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Background: The higher-order structure of chromatin changes in response to 
extracellular and environmental signals. We observed nuclear morphological 
changes in biopsied cancer tissue after chemotherapy. Since chromatin structure 
dictates gene expression, and therefore function, further investigation of this 
phenomenon may increase our understanding of therapeutic responses. I 
hypothesised that nuclear morphological changes in cancer in response to DNA-
damage by chemotherapy are mediated by histone deacetylases (de Ruijter, van 
Gennip et al.). Methods: Ovarian cancer cell lines PEO1/PEO4 (platinum 
sensitive/resistant) were selected as in vitro models, and primary ovarian cancer 
xenografts OV1002 and HOX424 as in vivo models. Expression levels of HDACs, 
heterochromatin protein 1 (HP1), and DNA damage response (DDR) proteins were 
profiled by Western blot analysis after treatment with cisplatin. Immunofluorescence 
imaging was undertaken using confocal microscopy, and nuclear texture and γH2AX 
foci were measured in Image J. Cell cycle and apoptosis were detected by flow 
cytometry. Thirty eight different ovarian cancer biopsies and 175 xenograft samples 
were assessed for HDAC and HP1 expression in response to chemotherapy by 
quantitative immunofluorescence. HDAC2 expression was modulated by interfering 
RNAs (siRNA). Results: I demonstrated nuclear morphological changes in clinical 
tumours, xenografts, and cell lines in response to platinum chemotherapy by robust 
measurement of nuclear texture. Expression of HDAC2 increased in PEO1 cells 
treated with cisplatin at 24h, and this was accompanied by high expression of HP1s. 
Expression of components of both HDACs and DDR pathways (pBRCA1, γH2AX, 
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pATM, pATR) showed time dependent changes after cisplatin treatment. 
Knockdown of HDAC2 reduced the expression of HP1, induced DNA double strand 
breaks (DSB) measured by γH2AX, and interfered with the activation of DDR 
induced by cisplatin. Furthermore, HDAC2 depletion affected γH2AX foci formation, 
cell cycle distribution, and apoptosis triggered by cisplatin, and was additive to the 
inhibitory effect of cisplatin in cell lines. By inhibiting expression of HDAC2, I 
observed reversible alteration of chromatin patterns during cisplatin treatment to 
some degree. In clinical ovarian cancer specimens, expression of HDAC4, HDAC8 
and HP1γ significantly increased after chemotherapy in sensitive patients, with 
enhanced heterogeneity in chromatin pattern. HDAC2, HDAC8, and HP1 expression 
were also increased after carboplatin treatment in carboplatin-sensitive xenografts. 
Conclusion: These results demonstrate alterations in nuclear morphology after 
chemotherapy, and implicate HDACs in having a role in higher order chromatin 
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1.1 Epigenetic regulation in cancers and cancer therapy 
From DNA, nucleosome, 30nm fibre, to higher order chromatin structure, human 
genomic DNA is extensively compacted. Appropriate organisation of DNA allows 
specificity of gene replication and expression. Recent studies have shown that 
chromatin is dynamic, with changes occurring within its structure and histone 
modifications during development and in response to extracellular signals (Ho and 
Crabtree 2010). Epigenetic change is defined as the modification of genome function 
without changes in DNA sequence, and has been extensively studied over the past 
few years, particularly in cancer research. 
There are at least four processes which contribute to changes in chromatin 
conformation (Figure1.1-1): DNA methylation, histone-tail acetylation, poly-ADP-
ribosylation, and ATP-dependent chromatin-remodelling mechanisms (Lafon-
Hughes, Di Tomaso et al. 2008). Different sets of modifications result in distinct 
readouts of genetic information (Margueron, Trojer et al. 2005; Santos-Rosa and 
Caldas 2005). As epigenetic changes are known to be mitotically heritable, their 
contribution to the development in cancer is undeniable (Akhtar and Cavalli 2005; 
Jones and Baylin 2007). Along with histone acetylation/deacetylation, discussed 
below in more detail, other modifications have been proposed to contribute to the 
connection between environmental factors and changes in gene expression in cancer. 
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Figure 1.1-1 Chromatin organisation and candidate players for epigenetic inheritance. (Probst, 
Dunleavy et al. 2009) 
 
DNA methylation acts as a heritable silencing mechanism through addition of methyl 
groups to cytosines.  These are found at dinucleotide CpG sequences, particularly in 
human tissues (Ehrlich, Gama-Sosa et al. 1982). Methylation occurs in about 60-90% 
spread CpG sequences, while those regions with a high CG content (CpG island) 
demonstrate a low level of methylation during development and in different tissues 
(Lafon-Hughes, Di Tomaso et al. 2008). This dynamic transcriptional silence varies 
between tissues and is critical for the expression of tissue-specific genes, X 
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chromosome inactivation, genomic imprinting, and differentiation (Robertson 2005; 
Meissner 2010). Apart from its physiological role, alteration of genomic DNA 
methylation can act as an important contributor to several pathological processes, 
such as immune diseases and cancer (Portela and Esteller 2010; Taberlay and Jones 
2011). As a well-identified chromatin modification mechanism, there is strong 
evidence that DNA methylation can act as an initial event in carcinogenesis. 
Hypomethylation of disperse CpG sequences and hypermethylation of CpG islands 
have been recognised as a hallmark in tumorigenesis with respect to epigenetic 
disruption in cancer (Sharma, Kelly et al. 2010). Identifying critical tumour 
suppressor genes silenced by DNA methylation in tumour induction and progression 
provides the basis for the development of targeted epigenetic therapies (Kelly, De 
Carvalho et al. 2010).  For instance, BRCAl can be hypermethylated in breast cancer, 
while promoters of the genes VHL, APC, and Rb are silenced through 
hypermethylation of CpG islands in renal cancers, colon cancers and retinoblastomas, 
respectively (Robertson and Jones 2000; Ting, McGarvey et al. 2006). 
By using the energy released from ATP hydrolysis, ATP-dependent chromatin-
remodelling complexes can alter the location of nucleosomes and regulate the gene 
transcription. This form of epigenetic remodelling has also been recognised as 
another contributory mechanism in oncogenesis (Jones and Baylin 2007). For 
instance, mutations in hSnf5, one of the remodelling complex members, have been 
found in paediatric choroid carcinomas and primary neuroectodermal tumours 
(Gibbons 2005; Vries, Bezrookove et al. 2005; Jones and Baylin 2007). Another 
study identified mutations in the BRG1 ATPase coding sequence, which is part of 
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one of the ATP-dependent remodelling complexes SWI/SNF, in non-small cell lung 
cancer (NSCLC) (Medina, Romero et al. 2008).   
Poly-ADP-ribosylation (PARlation) can produce poly-ADP-ribose (PAR), which 
consists of a homopolymer of ADP-ribose units under the activity of poly-ADP-
ribose polymerases (PARPs).  The main function of PARlation in chromatin 
remodeling is proposed to be involvement in histone modification and DNA 
methylation (Klenova and Ohlsson 2005), and it therefore acts as an important 
mechanism in chromatin structural regulation and gene expression in both normal 
tissues and cancers. Supporting this, there is evidence demonstrating that PARP 
(poly (ADP-ribose) polymerase) activity is elevated in adenomatous colon polyps 
and oral cancers (Das 1993; Shimizu, Nomura et al. 2004; Ratnam and Low 2007).  
It is now widely accepted that these chromatin modelling mechanisms do not 
function in isolation, but as part of a network, and crosstalk between different 
chromatin-remodelling mechanisms has been reported. It was observed that both 
chromatin acetylation and DNA methylation status corresponds to gene expression 
(Fischle, Wang et al. 2003). ATPases, the largest family of enzymes in the ATP-
dependent chromatin-remodelling mechanisms, have been described to interact with 
methyl DNA-binding proteins (Fitzgerald, DeLuca et al. 2004) and histone 
deacetylases (Saha, Wittmeyer et al. 2005).  
The importance of these epigenetic regulators during carcinogenesis and cancer 
progression provides novel therapeutic targets for cancer treatment. Various DNA 
methylation inhibitors and histone deacetylation inhibitors have been investigated in 
clinical trials (Olsen, Kim et al. 2007; Fenaux, Mufti et al. 2009).  The reversibility 
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of epigenetic chromatin remodelling also makes these targeted epigenetic therapies 
an exciting field to investigate with the hope of re-establishing a normal epigenome 
as part of effective cancer treatment. 
 
1.2 Histone acetylation/deacetylation modification and cancer 
One of the important chromatin modifications is the regulation of histone tails, which 
alters the accessibility of DNA to regulating enzymes by converting the chromatin to 
either a loose or tight structure (Figure1.2-1). By adding acetyl groups to the amino-
terminal tails of core histones, the acetylation of histones is the most common 
frequent post-translational histone modification (Davie 2003). Chromatin becomes 
decondensed and DNA accessibility is increased after acetylation of histone lysine 
residues, which reduces the force between the nucleosome core and negatively 
charged DNA (Lafon-Hughes, Di Tomaso et al. 2008). The acetylation status is 
determined by the balance between activity of histone acetyltransferases (HATs) and 
histone deacetylases (HDACs) (Kornberg and Lorch 1999). Alteration of histone 
acetylation is known to be involved in differentiation, mitosis and meiosis, DNA 
transcriptional regulation, DNA damage, DNA replication and circadian rhythms 
(Margueron, Trojer et al. 2005) (Jeppesen 1997; Hassa and Hottiger 2005; Williams, 






Figure 1.2-1 Process of histone tail acetylation and deacetylation during alteration of chromatin 
structure (McKinsey and Olson 2005). 
 
HATs are mainly classified into three groups due to their sequence similarity: GNA, 
MYST and p300/CBP (Yang 2004; Santos-Rosa and Caldas 2005; Verdone, 
Agricola et al. 2006), and 18 characterized mammalian HDACs are separated into 
four classes (Table 1.2-1) based on the structural homologies, enzymatic activities 
and cellular localisation (Gibbons 2005; Fog, Jensen et al. 2007; Gronbaek, Hother et 
al. 2007; Senese, Zaragoza et al. 2007). Class I HDACs are mainly located in the 
nucleus in a variety of tissues, and interact with both histones and other proteins 
(Acharya, Sparreboom et al. 2005; Santos-Rosa and Caldas 2005). Class II HDACs 
are expressed in a tissue dependent manner and can be detected in both nucleus and 
cytoplasm (Acharya, Sparreboom et al. 2005). Both Class I and Class II HDACs can 
be inhibited by the majority of HDAC inhibitors (Vannini, Volpari et al. 2004; 
Acharya, Sparreboom et al. 2005). Class III HDACs, namely sirtuins (SIRTs, silent 
information regulators), have no response to most inhibitors and work in the 
presence of the cofactor NAD+. Finally, the Class IV HDAC, which includes 
HDAC11 alone, is expressed in the nucleus and has homology with both class I and 
class II HDACs (Vannini, Volpari et al. 2004; Gronbaek, Hother et al. 2007).        
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Classifation HDAC members 
I HDAC1, HDAC2, HDAC3, HDAC8 
II IIa: HDAC4, HDAC5, HDAC7, HDAC9 
IIb: HDAC6, HDAC10 
III SIRT1, SIRT2, SIRT3, SIRT4, SIRT5, SIRT6, SIRT7 
IV HDAC11 
Table 1-1 Classfication of HDACs.  
 
HATs and HDACs activity can be altered by means of mutation, over-expression or 
translocation, disrupting the balance between acetylation/deacetylation, and 
consequently participating in the initiation and progression of some cancers. This has 
been demonstrated in leukaemia, prostate cancer, breast cancer, colorectal cancer, 
and ovarian cancer (Mahlknecht and Hoelzer 2000; Acharya, Sparreboom et al. 
2005). Three possible mechanisms are proposed in terms of deregulation of 
acetylation in carcinogenesis. Some tumour suppressor genes promoter regions, such 
as for p21, are silenced by histone hypoacetylation because of either HAT 
dysfunction or enhanced HDAC activity (Johnstone and Licht 2003; Gui, Ngo et al. 
2004). Conversely, increased HAT activity or reduced/absent HDAC function, 
resulting in histone hyperacetylation, could activate some repressed genes, causing 
abnormal expression of proteins and perhaps contributing to cancer initiation and 
progression. A third mechanism is suggested by which abnormal recruitment of 
HATs or HDACs could contribute to carcinogenesis (Acharya, Sparreboom et al. 
2005). Typical examples regarding the aberrant recruitment of HDACs are their roles 
during development of haematological malignancies. Fusion proteins composed of 
RAR (retinoid acid receptor), and its fusion partners PML and PLZF (coded by 
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promyelocyte gene and promyelocytic leukaemia zinc finger genes, respectively) due 
to chromosomal translocation are a conspicuous feature of acute promyelocytic 
leukaemia (APL). HDAC mechanistically plays an essential role by being recruited 
by those fusion proteins to form constitutive transcriptional repression of genes 
regulating normal differentiation and proliferation of myeloid cells, resulting in 
neoplasia by deregulating chromatin structure (Lin, Sternsdorf et al. 2001).   
The expression and role of HDACs in cancer have been reviewed and investigated in 
detail over the past few years. For a summary of these data, see Table 1.2-2. HDAC2, 
which has been intensively investigated in this study, enhanced expression has been 
shown to be associated with poor prognosis in pancreatic carcinoma (Miyake, 
Yoshizumi et al. 2008), and also in association with outcome in prostate, colorectal, 
and ovarian cancer (Weichert, Roske et al. 2008) (Jin, Pak et al. 2008; Weichert, 
Roske et al. 2008). Depletion of HDAC2 induced P21Cip1/WAF1-dependent apoptosis 
in cervical cancer cells (Huang, Laban et al. 2005), inhibited growth of breast cancer 
cells through senescence (Harms and Chen 2007), and also repressed proliferation of 
colon cancers cells (Weichert, Roske et al. 2008).       
 
Table 1-2 R





ilies in cancers (W
itt, D
eubzer et al. 2009). 
Meanwhile, HDAC inhibitors are intensively studied modulators of transcription and 
chromatin structure, and some inhibitors demonstrate efficacy in certain cancer 
therapies, making it an exciting strategy for cancer treatment. Those inhibitors are 
grouped into at least four classes: (1) hydroxamic acids, (2) aliphatic acids (Corbett, 
Blimkie et al.), (Corbett, Blimkie et al.) benzamides and (4) cyclic tetrapeptides 
(Kim and Bae 2011). The widely used inhibitor trichostatin A (TSA) is included in 
the hydroxamic acids class and was the first compound discovered to inhibit HDACs 
(Yoshida, Kijima et al. 1990). Another member of the first class, vorinostat 
(suberoylanilide hydroxamic acid, SAHA), was first utilised in the clinic for the 
treatment of refractory cutaneous T-cell lymphoma (CTCL) and was approved by the 
FDA (Duvic, Talpur et al. 2007). Other HDAC inbitors, such as entinostat, 
panobinostat, and abexinostat, are also in active clinical trials, as summarised in 




Table 1-3 HDAC inhibitor development and usage in clinical trials.  Abbreviations: CTCL, 
cutaneous T-cell lymphoma; SAHA, suberoylanilide hydroxamic acid (Khan and La Thangue 
2012). 
 
Various effects of HDAC inhibitors have been observed in tumour cells, including 
cell-cycle arrest, induction of apoptosis, and cell signalling pathway modulation. 
Several studies have suggested inhibition of HDACs may induce increased 
expression of the p21 gene (Richon, Sandhoff et al. 2000; Sandor, Senderowicz et al. 
2000; Gius, Cui et al. 2004; Ocker and Schneider-Stock 2007), and also repress 
transcription of genes encoding cyclin D and cyclin A (Qiu, Burgess et al. 2000; 
Sandor, Senderowicz et al. 2000) to trigger cell cycle arrest.  The apoptotic effect of 
Chemistry Compound Clinical status 
Hydroxymate SAHA (vorinostat) Approved (CTCL) phase 
II, III 
 PXD101 (belinostat) Phase I, II 
 LBH589 (panobinostat) Phase II, III 
 ITF2357 (givinostat) Phase I, II 
 PCI-24781 (CRA-024781) Phase I 
 JNJ-26481585 Phase I 
 4SC-201 (resminostat) Phase I, II 
Benzamide MS-275 (entinostat) Phase II 
 MGCD0103 (mocetinostat) Phase II 
Cyclic 
tetrapeptide Depsipeptide/FK228 (romidepsin) 
Approved (CTCL) phase 
I, II 
Aliphatic acids Valproic acid Phase I, II, III 





Pivanex (AN-9) Phase I, II 
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HDAC inhibition generally results from the increased regulation of pro-apoptotic 
genes (e.g. FAS and TNF-α) and decreased regulation of anti-apoptotic genes (e.g. 
BCL-2), which are involved in both the extrinsic and intrinsic apoptotic pathways 
(Stiborova, Eckschlager et al. 2012). Another essential property of HDAC inhibition 
is the regulation of some cellular pathways, such as the phosphatidylinositol 3-kinase 
(PI-3K)/Janus Kinase 2 (JAL2)/MEK-1 pathway (Bassa, Roh et al. 1999; Cieslik, 
Abrams et al. 2001) and Wnt signaling (Blaheta and Cinatl 2002) pathway. 
Although studies about HDACs and their role in epigenetic regulation have exploded 
since last ten years in cancer research, many problems remained unsolved. There is 
considerable evidence on the abnormal expression of HDACs in a variety of cancers, 
and even association with patient survival and treatment outcomes. However, the 
detailed mechanisms of how those HDACs are involved in progression and outcome 
still remain unclear. Questions are also raised about the therapeutic potential of either 
pan-specific HDAC inhibitors or class-specific HDAC inhibitors, and some observed 
side effects including diarrhoea, myelosuppression, and cardiac QT persistence are 
another challenge in applying HDAC inhibitors clinically (Ververis, Hiong et al. 
2013). Despite their antitumor activity, several HDAC inhibitors, including 
vorinostat and depsipeptide, show disappointing results in clinical trials of solid 
tumours as a single treatment, compared with its proven clinical advantage in 
hematological cancer therapy (Kim and Bae 2011). For example, vorinostat induced 
significant toxicities when treating patients with metastatic castration-resistant 
prostate cancer in a phase 2 trial (Bradley, Rathkopf et al. 2009). With continued 
investigation, improved knowledge of their modulatory roles on gene expression, cell 
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cycle progress, and proliferation will be better understood, and this will facilitate 
better application of HDAC inhibitors in the clinic, particularly as cancer therapies.  
 
1.3 The DNA damage response in chemotherapy 
1.3.1 DNA damage responses 
DNA damage is an extremely common event occurring in cells threatened by both 
endogenous or exogenous factors. Endogenous sources of damage mainly come from 
reactive oxygen products from cellular metabolic reactions, and also from errors 
during DNA replication. On the other hand, exogenous damage can be caused by 
factors such as ultraviolet radiation, ionising radiation, toxins, and compounds which 
interact with DNA. Those agents can induce a variety of different types of DNA 
damage, as illustrated in Figure1.3-1, which then are repaired by specific DNA repair 
mechanisms to preserve genome stability.   
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Figure 1.3-1 Types of DNA damage and the associated repair mechanisms. Both endogenous 
and exogenous agents can induce several types of DNA damage,lesion, and corresponding 
repair process can be involved based on the different damage type. Abbreviations: cis-Pt, 
cisplatin; MMC, Mitomycin C; (6 4)PP, 6-4 photoproduct; CPD, cyclobutane pyrimidine dimer; 
BER, base-excision repair; NER, nucleotide-excision repair; HR homologous recombination; 
NHEJ non-homologous end joining (Martin 2001).  
  
There are four main types of DNA repair processes. These are base-excision repair 
(BER), nucleotide-excision repair (NER), homologous recombination (HR), non-
homologous end joining (NHEJ), and mismatch repair. BER is mainly involved in 
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the repair of endogenous damage from base changes, in order to to prevent 
miscoding mutations,. NER repairs damage in helix-distorting lesions which 
particularly impede transcription and replication. These two mechanisms are both 
associated with single strand damage, and lesions can be repaired by replacing the 
damaged sequence with the correct sequence based on the complementary strand in a 
‘cut and patch’ manner (Hoeijmakers 2001). 
In contrast, the repair processes of homologous recombination (HR) or non-
homologous end joining (NHEJ) are involved in the repair of severe damage which 
involves both DNA strands (Martin 2001). They have been intensively studied over 
several decades (Figure1.3-2). NHEJ functions through direct ligation of the double 
strand break (DSB) ends with the assistance of double-stranded DNA end-binding 
protein complex Ku70/80, although this simple re-ligation is error-prone  and can 
lead to the addition of small nucleotides or deleted sequence at the damaged site 
(Lieber 2010). On the other hand, HR is considered error free repair. After resection 
of the damaged site, the recombinase filament on the resection-induced single-strand 
tails facilitate the use of the homologous sequence as a template in a conservative or 
non-conservative manner (San Filippo, Sung et al. 2008). Because of the nature of 
these two repair methods, NHEJ can occur throughout the cell cycle, but it is 
suggested that it occurs more frequently during G1 phase. HR occurs typically after 
normal DNA replication when the non-damaged homologous sister chromatid serves 
as a template for repair synthesis (Chapman, Taylor et al. 2012). 
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Figure 1.3-2 Process of DNA double strand break repair by homologous recombination (HR) or 
non-homologous end joining (NHEJ) (Kee and D'Andrea 2010). 
        
With continued, advanced biochemical studies of DNA damage over the past 15 
years, the knowledge of the DNA damage response (DDR) has expanded in concept 
and range. The notion of DDR now includes the sensors which detect the damage, 
mediators which function as both recruiters and scaffolds at damaged sites, effectors 
controlling the direction of response, and interconnections with a variety of pathways 
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such as cell cycle and chromatin remodeling. In addition there have been important 
advances with respect to chromatin regulation and ubiquitin during DDR, as 
summarized in Figure1.3-3 (Harper and Elledge 2007). 
 




































1.3.2 Mechanisms of cisplatin-induced DNA damage response 
Platinum-based drugs are used as cancer therapy for a wide variety of solid tumours. 
The cis-diammine-dichloroplatinum(Akahira, Sugihashi et al.) is one of the most 
widely used platinum drugs, and is also known as cisplatin or CDDP. It has been 
used in the clinic as chemotherapy for several cancers, including testicular, bladder, 
ovarian, colorectal, lung, and head and neck neoplasms (Galluzzi, Senovilla et al. 
2012). Carboplatin and oxaliplatin are analogues to cisplatin, and are also used as 
cancer treatments. However, either intrinsic or acquired resistance to cisplatin still 
remains as a critical problem for anticancer therapy. 
The success of cisplatin as an anti-tumour drug is associated with its interaction with 
DNA, where it forms platinum-DNA adducts, which are known as cisplatin-induced 
DNA damage. The drug mainly reacts with N7 site of purine bases in DNA, and 
forms intrastrand crosslinks and a low ratio of interstrand crosslinks (ICLs), as is 
shown in Figure1.3-4. The intrastrand crosslink with G residues is considered to be 
more damaging (Basu and Krishnamurthy 2010). The distorted DNA structure 
interferes with normal replication and activates cell cycle checkpoints which result in 
cell death (Comess, Burstyn et al. 1992; O'Brien and Brown 2006; Basu and 
Krishnamurthy 2010).     




Figure 1.3-4 Cisplatin-induced DNA crosslinks. A. The structure of cisplatin. B. Reaction 
between cisplatin and guanine bases. C. Intrastrand crosslinks induced by cisplatin. D. 
Interstrand crosslinks formed by cisplatin. 
 
The DNA intrastrand crosslinks caused by cisplatin can be repaired via nucleotide 
excision repair (NER). Two components in this pathway, Xeroderma Pigmentosum 
complementation group A (XPA) and excision repair cross-complementation group I 
(ERCCI), are believed play essential roles for this repair process, and increased 
expression of ERCC1 and XPA proteins have been implicated in cisplatin resistance 
(Wu, Fan et al. 2003). Although there is low ratio of ICLs (5%) induced by cisplatin 












separation, obstructing replication. Recognition of ICLs relies on the Fanconi anemia, 
complementation group M (FANCM) complex to send signals of damage to 
downstream effectors and recruit cell cycle checkpoint proteins and repair 
components. The replication protein A (RPA)-ataxia telangiectasia and Rad3-related 
(Kothandapani, Dangeti et al.)-CHK1 signaling is typically responsible for cell cycle 
regulation in response to this type of damage. BRCA1 and BRCA2 complexes 
trigger the activation of HR repair for these double strand breaks (Deans and West 
2011). H2AX can be immediately phosphorylated on the C-terminal Ser139, namely 
γH2AX, which accumulates at damaged sites. Therefore γH2AX has been widely 
used as a biomarker of DSBs. It also plays a principle role in the recruitment and 
activation of a range of downstream DNA damage response proteins, such as ataxia 
telangiectasia mutated (Miyake, Yoshizumi et al.), ATR, BRCA1, and DNA-PK 
(Hartlerode and Scully 2009). In addition to these pathways, other signaling 
pathways controlling cell growth, cell cycle arrest, apoptosis, differentiation and 
cellular stress responses have also been elucidated to participate in the process of 
DDR induced by cisplatin. These include proteins such as p53, p73, JUN amino-
terminal kinase (JNK) and p38 mitogenactivated protein kinase (p38MARP) (Siddik 
2003; Kelland 2007).  
The cellular DDR induced by cisplatin is a well understood process with various 
steps and pathways involving an orchestrated and tightly regulated network; however, 
there are still gaps in our understanding of the mechanisms of this response. One of 
the crucial unresolved issues is: how and why does cisplatin resistance occur in 
cancer treatment? It has been pointed out that the success of chemotherapy is 
dependent not only on its capacity to cause DNA damage, but also on a cell’s 
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susceptibility to sense and respond to the damage (Kerr, Winterford et al. 1994; Basu 
and Krishnamurthy 2010).  However, the toxic effects of chemotherapeutics are a 
common issue that compromises cancer treatment for patients. Toxicity effects 
include immunosuppression and myelosuppression, secondary neoplasm, infertility, 
neurological adverse effects, and organ damage, so the balance between applying an 
adequate dose to damage cancer cells and maintaining minimal and acceptable side 
effects becomes an essential goal during chemotherapy (Felici, Verweij et al. 2002; 
Liu, Chen et al. 2011). In this case, combination treatments of cisplatin with drugs 
targeting those pathways which sense and respond to damage are urgently required to 
improve chemotherapy efficacy and overcome resistance. Detailed investigation 
about the mechanisms involved in the cellular responses to cisplatin are likely to 
provide novel targets for therapy and development of better strategies for effective 
anticancer therapy.   
 
1.4 Chromatin remodeling in DNA damage responses 
Over the past twenty years, chromatin remodelling has become one of the most 
essential fields contributing to our understanding of DDR, due to the intimate 
association between chromatin conformation and the ability of cells to repair damage. 
A wide range of research has implicated chromatin remodelling in the DDR process. 
 
 41 
1.4.1 Crosstalk between chromatin modification and the DNA damage 
response 
Unsurprisingly, how chromatin is packaged can definitely influence the response of a 
cell to DNA-damaging agents. Initial investigations established that depletion of 
histones induced sensitivity to extracellular ionising radiation, compared with 
condensed chromatin where transcription is silenced (Elia and Bradley 1992). 
Several studies have revealed the impact of chromatin structure on DDR process at 
the sites of DNA damage. Increased DDR signalling was detected when condensed 
chromatin was pharmacologically perturbed by expressing a galactose-inducible HO 
endonuclease, and H2AX phosphorylation mainly remained within areas in 
accessible chromatin (Kim, Kruhlak et al. 2007; Di Micco, Sulli et al. 2011). 
Moreover, the DSBs triggered by ionising radiation were prolonged within compact 
chromatin (Cowell, Sunter et al. 2007). However, the concept that an accessible 
chromatin environment facilitates DDR has recently been challenged. The spread of 
γH2AX was impeded within open chromatin regions where RNA polymerase II was 
recruited, and gene transcription was regulated within γH2AX domains (Iacovoni, 
Caron et al. 2010). In particular, there have been recent investigations into the effect 
of chromatin context on DNA damage repair. It has been shown that repair of DSBs 
near or within condensed chromatin is inefficient (Sulli, Di Micco et al. 2012). On 
the other hand, it has been demonstrated that homologous recombination-mediated 
DNA repair could be assisted by recruiting an important component of constitutive 
heterochromatin, namely heterochromatin protein a (HP1) (Baldeyron, Soria et al. 
2011). A recently proposed dynamic model may explain these conflicting findings: 
noticeable DNA damage in compacted chromatin might only occur very early after 
 42 
damage, and DSBs then progress outside the heterochromatic region to complete 
DNA repair (Chiolo, Minoda et al. 2011; Sulli, Di Micco et al. 2012). The exact 
mechanism by which the pre-existing and dynamic chromatin environment 
contributes to DDR has not been clearly identified.        
More recently is has also been proposed that the chromatin alterations induced by 
DDR activation differ both at the site of the DNA damage lesion, and throughout the 
whole genome. Dynamic expansion of condensed chromatin was observed in 
response to ionising radiation (IR) in Drosophila cells, and chromatin with DSBs 
experienced a local expansion after DNA damage to a more open structure of 
chromatin fibers in a H2AX and ATM independent manner (Kruhlak, Celeste et al. 
2006; Chiolo, Minoda et al. 2011).  It has also been shown that DSBs cause an ATP-
dependent chromatin de-condensation, and chromatin modification results in the 
initial events of DDR signalling activation, including ATM phosphorylation at 
serine1981 (Bakkenist and Kastan 2003). Meanwhile, DNA breaks release 
heterochromatin protein 1 (HP1)-beta to induce chromatin structure alterations and 
promote H2AX phosphorylation in mammalian cells, and this mobilization of HP1-
beta relies on HP1-beta phosphorylation on Thr51 (Ayoub, Jeyasekharan et al. 2008). 
In addition, dynamic changes in the undamaged homologous chromosome were also 
observed to facilitate DDR signalling, dependent on activation of Rad51 
recombinase. This provides evidence that DNA damage-induced chromatin 
modulation occurs globally in the genome other as well as at damaged sites (Mine-
Hattab and Rothstein 2012).  
Although the fact that chromatin relaxation induced by DDR facilitates downstream 
response signaling has been proven in several studies, there are also remarkable 
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evidence demonstrating the existence of compact chromatin following DNA damage. 
Luijsterburg and colleagues observed the recruitment of components of condensed 
chromatin, HP1 proteins, to the DSBs sites induced by ultraviolet radiation in human 
cells, which was suggested to be essential for DNA repair and chromatin 
reorganization in cellular DDR (Luijsterburg, Dinant et al. 2009). HP1 recruitment 
has been identified within damaged regions in both heterochromatin and euchromatin 
immediately after DNA damage (Zarebski, Wiernasz et al. 2009). In another study, 
chromatin decondensation which was dependent on RNA polymerase II elongation 
was repressed during DNA damage, which was inhibited by ATM (Shanbhag, 
Rafalska-Metcalf et al. 2010). Furthermore, as a silent marker within compacted 
chromatin, hypermethylated CpG islands were also observed in DSB DNA to 
suppress the transcription of genes near damaged sites, which suggested an important 
role for hypermethylated CpG islands in the maintainance of a stable alteration of 
damage ie so that there is no propagation of damage (O'Hagan, Mohammad et al. 
2008; Lee, Kim et al. 2010). In this scenario, by compacting chromatin within the 
damaged sites, the cell protects itself from further potential injury from exogenous 
damage and transcription with DSBs by constructing an isolated region where repair 
and other DDR downstream signalling may progress. 
It can be argued that the conflicting observations about chromatin structural 
alterations in response to DNA damage might be due to differing experimental 
conditions and the models applied in those studies. However, they also provide 
evidence which highlights the comprehensive network of chromatin reorganisation 
induced by DNA damage and its role in the DDR pathways. Although there are 
evidence showing the importance of genome stability for a cell to respond effectively 
 44 
to DNA damage, and studies proving nuclear changes are triggered by DNA damage, 
their relationship and underlying mechanisms are incompletely understood and still 
deserve to be investigated. 
 
1.4.2 Histone acetylation and DDR signalling 
As discussed above, chromatin remodelling and DNA damage response pathways 
interact with each other in an extremely complex network. The conflicting 
observations about chromatin decondensation and condensation after DNA damage 
can be acceptably explained by a study suggesting biphasic chromatin modification 
after the induction of DNA damage. The authors propose that rapid histone 
hypoacetylation occurs after DSBs to generate a compressed chromatin condition 
which facilitate NHEJ. This is followed by histone acetylation to create accessible 
chromatin architecture which promotes HR (Miller, Tjeertes et al. 2010).  
Initial investigations into the role of histone acetylation indicate the requirement of 
acetylation of lys56 on histones (H3H3k56Ac) for nucleosome reorganisation after 
damage, and participation in DNA repair (Masumoto, Hawke et al. 2005; Chen, 
Carson et al. 2008). In contrast, it has recently been shown that level of H3K56Ac 
decreased rapidly after DNA damage, and is associated with localisation of HDAC1 
and HDAC2 to the damaged sites (Tjeertes, Miller et al. 2009; Miller, Tjeertes et al. 
2010). HDAC1 was also found to play an important role in the DNA damage 
response by cooperating with the ATR checkpoint in DSBs, initiating autophagy 
(Robert, Vanoli et al. 2011). HDAC inhibition causes relaxation of condensed 
chromatin and enhanced DDR signalling and apoptosis (Di Micco, Sulli et al. 2011). 
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After treatment with the HDAC inhibitor PCI-24781, colon cancer cells demonstrate 
a significantly reduced ability for HR, with decreased transcription of HR-related 
genes, including Rad51, and increased sensitivity to radiation treatment as shown by 
decreased colony formation in vitro (Adimoolam, Sirisawad et al. 2007). Another 
line of evidence is that depletion of both HDAC1 and HDAC2 supress DSB repair 
with a slightly decrease in homologous recombination and abundant reduction in 
NHEJ (Miller, Tjeertes et al. 2010). This is consistent with the finding of 
overexpression of HDAC1 and HDAC2 in many tumours, especially malignant ones, 
possibly with the reason that they are required to modify histones and facilitate 
effective DNA repair during DNA damage (Fraga, Ballestar et al. 2005).  Another 
study showed that depletion of HDAC5 sensitised sells to DNA-targeted agents and 
induced more apoptosis, and elucidated involvement of HDAC for the maintenance 
of heterochromatin structure (Peixoto, Castronovo et al. 2012). In addition, HDAC 
inhibitors enhanced sensitivity to DNA-damaging reagents in six human ovarian 
cancer cell lines with different cisplatin sensitivities, induced accumulation of 
γH2AX, and enhanced cell death with the combination treatment with DNA-
damaging drugs (Ozaki, Kishikawa et al. 2008). 
HDAC inhibitors show potential effectiveness in cancer treatment, but knowledge of 
how these inhibitors work is still unclear. By understanding the complex interplay 
between HDAC and DNA damage-induced responses in cancer therapy we can 
develop more effective strategies for the combination treatment of tumours with 
HDAC inhibitors and DNA-damaging reagents.    
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1.5 Heterochromatin and heterochromatin proteins 
Heterochromatin is cytologically defined as nuclear regions where DNA is highly 
compacted (Figure 1.5-1), and it constitutes about 15-25% of mammalian DNA 
(Murray, Stiff et al. 2012). Heterochromatin plays an important role in the silencing 
of gene expression and to guard to genome integrity. The formation of 
heterochromatin required methylation of histone H3 at lysine 9 (H3K9me) and 
heterochromatin protein 1, HP1 (Piacentini, Fanti et al. 2003; Vakoc, Mandat et al. 
2005). Studies have also demonstrated that heterochromatin proteins play a role in 
the recruitment of mediators which recruit RNA polymerase II (Pol II) to 
heterochromatin regions (Zofall and Grewal 2006).   
 
Figure 1.5-1 Compaction of heterochromatin (Adcock, Ford et al. 2006). 
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Heterochromatin protein 1 (HP1) is one of the essential components constituting 
heterochromatin and it plays various roles in establishing and maintaining 
heterochromatin structure, which leads to repressed transcription (Cheutin, McNairn 
et al. 2003). It has been reported that HP1 overexpression could cause global gene 
repression and /or chromatin condensation (Popova, Claxton et al. 2006; Dialynas, 
Vitalini et al. 2008). There are three HP1 proteins identified in human genome: HP1 
alpha (HP1α), HP1 beta (HP1β), and HP1 gamma (HP1γ), and they share some 
functions and localise to chromatin with incomplete overlapping (Minc, Allory et al. 
2001). These proteins demonstrate different localszation to centric heterochromatin, 
telomeres and specific sites within euchromatin (James, Eissenberg et al. 1989). 
Alterations in protein expression of HP proteins have been identified in some cancers 
in several studies, including ovarian cancer (Maloney, Clarke et al. 2007), breast 
cancer (Kirschmann, Lininger et al. 2000), and colorectal cancer (Ruginis, Taglia et 
al. 2006). Thus, along with their roles in chromatin remodelling during DDR, HP1 
proteins are used in these studies as a marker for heterochromatin and the level of 
condensation of chromatin. We hypothesise that if HDAC protein(s) is/are involved 
in this ‘protective’ response in cells by which gene silencing occurs in order to assist 
cells to survive via a chromatin remodelling mechanism, then there will be alteration 
of HP1 protein expression and/or distribution within nuclei.  
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1.6 Nuclear morphology studies during cancer treatment 
Cellular morphological studies (ie cytology and histopathology) are essential and 
useful in the evaluation of stem cell differentiation, and diagnosis of haematological 
and solid organ malignancies. These techniques are also used to examine responses 
to therapies, especially in cancer treatment; however, there is only limited research 
on the cellular and nuclear morphological responses caused by treatment. Early 
studies demonstrated alteration of cellular morphology with loss of polarity and 
fragmentation of nuclei into micronuclei after taxol treatment (Tishler, Schiff et al. 
1992). Nuclear abnormalities, in the form of enlarged nuclei and polyploidy, have 
also been in the livers of perinatal embryos with ERCC-1 deficiency (McWhir, 
Selfridge et al. 1993). A detailed description was made in a study, stating that 
chemotherapy-responding ovarian tumours showed low nuclear:cytoplasmic ratio 
and irregular nuclear outlines with clumped chromatin after chemotherapy, and 
remarkable stromal changes were also noticed (McCluggage, Lyness et al. 2002). In 
another study, cellular morphological alterations were seen after treatment with the 
HDAC inhibitor, SAHA. Cell size was enlarged and they became flattened after 
treatment, and nuclei also exhibited distinct borders and less visible nucleoli 
(Munster, Troso-Sandoval et al. 2001).         
With only limited descriptions about cellular morphological alterations during or in 
response to cancer treatment, our knowledge about these pathological responses are 
still in their infancy. Further investigation is deserved to establish the biological 
meaning of these observation and link these visible changes to fundamental cellular 
mechanisms during anti-cancer therapy.  
 49 
 
1.7 Observations and preliminary studies 
1.7.1 Nuclear pathological changes were observed in damaged cells  
Examining the histopathological characteristics of tissues is gold-standard for disease 
diagnosis, especially in cancer. This also provides opportunity to observe any visible 
morphological changes within cells, for example changes in nuclei. Under the 
microscope, quite similar pathological changes of chromatin pattern and condensity 
are observed in the nuclei in ovarian tumours after chemotherapy (Figure 1.7-1A), 
breast tumours after chemotherapy (Figure 1.7-1B), and colorectal tumours post-







































   
 
Figure 1.7-1 Similar nuclear texture changes occur in A. ovarian tumours after chemotherapy, B. 
breast tumours after neoadjuvant therapy, and C. colorectal tumours after radiotherapy, D. 
ovarian tumour xenografts, and E. ovarian cancer cell line PEO1 after cisplatin treatment under 
microscope.  A-D are formalin-fixed, paraffin embedded sections cut from tumour samples, and 
stained by H&E. E are cytospinned PEO1 cells from cell culture using Feulgen stain to indicate 
















    Feulgen 
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The nucleus (purple areas in H&E-stained samples and pink areas in Feulgen-stained 
samples) tends to be much more heterogeneous either after radiotherapy or 
chemotherapy, which may be regarded in a general sense as cellular injury. Tissue 
damage or changes occur after exposure to ionising radiation from radiotherapy or 
receiving chemical drugs due to their cytotoxity in chemotherapy, as described above. 
In addition, similar changes occurred in ovarian tumour xenografts (Figure1.7-1D) 
during carboplatin treatment and the ovarian cancer cell line PEO1 (Figure1.7-1E) 
treated with cisplatin. Thus this phenomenon about nuclear change appears to be 
quite general.   
 
1.7.2 A histone deacetylase is potentially associated with response to 
chemotherapy in ovarian cancers 
As discussed above, chromatin change may manifest itself as peripheralisation, 
which is known to be associated with methylation/acetylation of histones and gene 
repression, after chemotherapy or radiotherapy injury. This peripheralisation has also 
been reported in cells containing double strand breaks (DSBs) after DNA damage 
(Oza, Jaspersen et al. 2009).  
Initially, a V250 antibody microarray was used to investigate differential 
phosphoprotein expression of 125 selected signalling proteins related to cancer 
among a range of ovarian cancer cell lines in our lab (unpublished data, D. Faratian). 
The V250 proteomic data (Figure 1.7-2) showed that phosphorylation of histone 
deacetylase, particularly HDAC8 (indicated by ‘deacetylation’ in the heatmap), was 
the top discriminator between clusters in an unsupervised analysis of ovarian cancer 
cell lines (p=0.001, t-test). These clusters (cluster A and cluster B) appeared to be 
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associated with exposure to therapy/platinum resistance (see table 1.7-1 for the 
information about cell lines). Thus this indicated a possible association of HDAC 
proteins with response to chemotherapy in ovarian cancer, and we speculated that 
HDAC might be a factor that mediates resistance to, or might be a therapeutic target 




Figure 1.7-2 V250 proteomic data in an unsupervised analysis of ovarian cancer cell lines. 
Heatmap was generated from averaged values of normalised phospho:non-phospho ratio of 
125 selected proteins summed as ontological groups to give a global overview of pathway 
changes (indicated on the right side of the heatmap). 12 ovarian cell lines are classified into two 
groups, as shown in the right panel. The full list of proteins included and grouped in different 
pathways in the study are shown in Table S7. Deacetylation refers to phospho:non-phospho 
ratio of HDAC8.   
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Cell line  Histotype Source Treatment/resistance 
PEO1 Poorly differentiated 
serous adenocarcinoma 
Ascites Platinum treated and sensitive 
PEO4 Poorly differentiated 
serous adenocarcinoma 
Ascites Platinum resistant 
OVCAR3 Poorly differentiated 
papillary 
adenocarcinoma 
Ascites Cisplatin/ cyclophosphamide/ 
adriamycin treated 
OVCAR4 Adenocarcinoma Ascites Cisplatin/ cyclophosphamide/ 
adriamycin treated 
OVCAR5 Adenocarcinoma Ascites None-treated 
SKOV-3 Adenocarcinoma Ascites Thiotepa treated 
OAW42 Serous adenocarcinoma Ascites Cisplatin treated 




ES2 Clear cell carcinoma Primary 
tumour 
None-treated 
TOV112D Endometrioid carcinoma Primary 
tumour 
None-treated 
TOV21G Clear cell carcinoma Primary 
tumour 
None-treated 
Table 1-4 Properties of Ovarian cell lines used in V250 study. 
 
1.8 Hypothesis and aims 
As cancer drug resistance, especially acquired resistance, becomes a more pressing 
clinical concern for doctors treating patients with recurrent disease, mechanistic 
research into responses to treatment are of increasing importance. Dynamic structural 
remodelling of chromatin has a potential role during DNA damage-inducing 
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therapies, but large part of how they work together remains unknown. Our 
preliminary studies demonstrate quite general observations about global nuclear 
changes in morphology, and histone acetylation may be involved in the response to 
chemotherapy. As one of the important chromatin modifiers, we speculate that 
HDACs may play a causative role in these damage-induced nuclear changes. We 
therefore hypothesise that nuclear morphological changes in cancer in response to 
DNA-damage by chemotherapy are mediated by histone deacetylases (HDACs). To 
further understand in more detail the molecular processes behind these 
morphological alterations and identify novel mechanisms of ovarian cancer 
resistance, there are several issues which will be addressed using various techniques: 
1: Do nuclear changes occur in response to injury and what is the cellular effect (+/-
HDAC as key mediator)?  
• Establishing tractable cell line models  
• Establishing robust quantification of nuclear changes with image analysis 
and/or other markers 
• Detecting nuclear phenotype alteration after therapy (platinum), 
with/without inhibition of HDAC 
• Analysing nuclear morphological changes in clinical ovarian samples pre- 
and post-treatment and in in vivo models 
• Measuring other markers of heterochromatin (e.g. HP1 proteins) 
• Quantifying apoptosis, cell cycle, DNA-damage in cells exhibiting the 
phenomenon 
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• Detecting the reversibility with withdrawal of stimulus 
2: Is HDAC a resistance factor to DNA-damaging therapy and how does it mediate 
its effect? 
• HDAC expression with chemotherapy confirmed in cell lines by WB or 
PCR 
• Quantifying HDAC and HP1 expression pattern in vivo (using ovarian 
xenografts) 
• Inducing sensitivity with HDAC depletion 
• Reversing sensitivity in cancer cells to establish functions of HDAC 
proteins in cellular DNA damage response induced by platinum 
• Evaluation the cellular effect of DDR after HDAC depletion such as cell 
cycle distribution and apoptosis induction 
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2 Materials and Methods 
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2.1 Cell culture 
Cells were always grown in a humidified atmosphere of 5% CO2 at temperature of 
37°C. 
2.1.1 Routine cell line culture conditions 
For cell culture, these cells were grown as monolayer cultures in RPMI 
supplemented with 10% heat-inactivated fetal calf serum (FCS) and penicillin / 
streptomycin (100IU/mL).  
2.1.2 Subculturing of cells 
For continuing growth, cells were passaged when cell number achieved 80-90% 
confluence. Media was removed and cells were washed with warmed PBS once. 
After incubation with trypsin for a few minutes in the incubator, media was added to 
neutralise the trypsin and cells were spun down at 285 x g for 4 minutes. The pellets 
were re-suspended in normal culture media and transferred into flasks at an 
appropriate dilution.  
2.1.3 Cell culture for drug treatment 
All the experiments in terms of drug treatment utilised this protocol unless otherwise 
stated. Cells were harvested in RPMI supplemented with 10% heat-inactivated FCS 
and penicillin / streptomycin (100IU/mL) for 72h before drug treatment. 
2.1.4 Cryopreservation and cell recovery from liquid nitrogen 
Cells were grown to 80-90% confluence in a 175cm2 flask, trypsinised, and 
centrigued at 285 x g for 4 minutes. Cell pellet were then resuspended in about 5ml 
of Freeze Mixture-heat-inactivated FCS/10% DMSO, and aliquoted into 
cryopreservation vials. All the cells were frozen and stored in the liquid nitrogen 
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storage room of Breakthrough Breast Cancer Unit (Western General Hospital, 
Edinburgh) until needed. 
To recover cells from liquid nitrogen, cell samples were thawed and transferred into 
a 25ml universal container, and warm normal culture media was added to make up a 
volume of 25ml. After centrifugation at 285 x g for 4 minutes, cell pellets were 
resuspended in fresh media and transferred into a suitable flask for routine culture.  
  
2.2 Knockdown of HDAC2 in PEO1 and PEO4 cells with RNAi 
The knockdown work for HDAC2 by transfecting RNAi to cells was conducted in 
60mm cell culture dishes, and the reverse transfection method was performed as the 
manufacture’s instruction. 
Briefly, the RNAi duplex-LipofectamineTM RNAiMAX complexes were prepared 
as follows. 
        a. 10-100pmol RNAi duplex was diluted in 500µl Opti-MEM® I Medium 
without serum in each cell culture dish and mixed gently. 
        b. LipofectamineTM RNAiMAX was mix gently, 0.8 µl of which were added to 
each dishes containing the diluted RNAi molecules. The mixture was incubated for 
20 minutes at room temperature. 
After the incubation, cells were diluted in complete growth medium without 
antibiotics with the concentration of 700,000 – 800,000 cells/ 5mL so that cell 
density would be 30-50% confluent 24hours after seeding. To each well with RNAi 
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duplex-LipofectamineTM RNAiMAX complexes, 5mL of the cell mixture was 
added, and also mixed gently by rocking the plate back and forth. 
Several control groups were also included in experiments to detect the efficiency of 
knockdown: untransfected control group without any of transfection agents, mock 
group only with LipofectamineTM RNAiMAX mixture, and negative control group 
with the random RNAi duplex containing similar range of GC content to siHDAC2. 
The cells and the complexes were incubated for 24-120h at 37oC in full serum 
without antibiotics. For drug treatment, cisplatin was added after 48 hours of 
transfection, and cells were collected after several time points as indicated.  
 
2.3 Xenograft models 
Two systematic mice models were established in our lab model OV1002 and model 
HOX242. Female adult CD-1 nude mice housed in IVCs (individually ventilated 
cages) were treatment with Carboplatin (50 mg/kg i.p.) on Day 0, and tumour 
samples were collected on Day0, 1, 4, 7, and 14 after treatment. Model OV1002 
showed much more sensitive to carboplatin treatment compared with HOX242. 
2.4 Cell proliferation analysis by Sulforhodamine B assay 
Cells were harvested in log phase, then split by trypsin, counted using a 
haemocytometer and optimal initial numbers of cells in an aliquot of 200 uL per well 
were seeded into 96 well cell culture plates in a humidified atmosphere of 5% CO2 at 
37°C for 72h. Cells were then treated with reagents specified in result section. After 
incubation for 0-6 days with testing materials, cells were fixed by 25% cold 
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trichloroacetic acid (50uL/well), and incubated for 1h at 4°C. Plates then were 
washed with running tap water by ten times and air-dried in a warm oven (50°C), 
after which cells were stained with sulforhodamine B dye (0.4 % solution in 1 % 
acetic acid, 50 µl/well) for 30 min. After washed with 1% acetic acid by 4 times, 
plates were dried in the oven again. 100uL Tris buffer (10mM, pH 10.5) were added 
into each well 1h prior being read and were shaken gently during the incubation. The 
optical density (OD) was recorded using Biohit BP800 Microplate reader at 540 nm.  
 
2.5 Protein extraction from mammalian cell lines 
Cells were harvested in log phase, plated into 60mm petri dishes and incubated for 
72hr or specified period after treatment. After the incubation, cells were washed in 
cold PBS, and lysed with scraping in ice-cold isotonic lysis buffer [50mM Tris-HCl 
(pH7.5), 5mM EGTA (pH 8.5), 150mM NaCl, 1% Triton X-100] supplemented with 
aprotinin (10 µg/mL) and a ‘Complete’ Protease Inhibitor Cocktail Tablet (Roche, 
11836153001) for 30min on ice. Lysates were then centrifuged for 6min at 13,000 × 
g. The supernatant was recovered as cleared cell lysate and sorted at -70°C.  
2.6 Protein quantification 
This assay is carried out in 12 x 75mm borosilicate glass tubes (Fisher; 14-961-26). 
A 1mg/mL protein standard in 0.15M Sodium Chloride (Sigma; P0914-5AMP) was 
used to create an 8-point standard curve.  Protein concentrations were determined 
using the Bicinchoninic Acid (BCA) assay (Sigma, BCA-1). In brief, 1 part of a 
protein was mixed with 20 parts of the BCA Working Reagent and then incubated 
for 15min at 60°C. Absorbance of the sample solution was measured at 562 nm using 
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Microplate reader (Biohit BP800). Protein concentration was then calculated using 
the standard curve generated from known standards. 
 
2.7 SDS polyacrylamide gel electrophoresis  
The separation of proteins on the basis of their electrophoretic mobility was achieved 
by denaturing sodium dodecyl sulphate polyacrylamide gel electrophoresis (SDS-
PAGE), using the vertical electrophoresis system (Bio-Rad, Mini-PROTEAN® 3). 
Concentrations of polyacrylamide gels were 10%. First, the resolving gel (8-12% 
Acrylamide, 390mM Tris-HCl pH8.8, 0.1% SDS, 0.1% APS, polymerisation was 
initiated by adding 0.08% TEMED) was set up in a gel caster and was overlaid with 
isopropanol or distilled water in order to remove air bubbles. After the resolving gel 
was polymerised at room temperature, the isopropanol was removed followed by 
setting up of the stacking gel (5% Acrylamide, 123mM Tris-HCl pH6.8, 0.1% SDS, 
0.1% APS, 0.1% TEMED). 25ug of each protein lysate sample was prepared in SDS-
PAGE sample buffer and was heated at 60°C for 60min, and then loaded on to the 
gel and electrophoretically resolved with protein ladder (Prestained Protein Marker, 
Broad Range, 7-175 kDa, New England Biolabs) in the running buffer (192mM 
Glycine, 25mM Tris, 0.1% (w/v) SDS) at 80V for the stacking gel and 140V for the 
resolving gel. 
Since their large molecular weight, AMT, pATM, ATR, and pATR were analyzed by 




2.8 Western blotting 
After the SDS-PAGE, the resolved proteins were electrophoretically transferred onto 
a nitrocellulose membrane at 30V, 4°C overnight. After transfer, membranes were 
rinsed in PBST and then blocked with Li-Cor Odyssey Blocking Buffer (diluted 
50:50 in PBS) for 1h at room temperature before probing overnight at 4°C with the 
appropriate primary antibody made up in Li-Cor Odyssey Blocking Buffer (diluted 
50:50 in PBS) using 1:1000 dilution.  Primary antibodies used for western blotting 
were listed in Table 2.2-1. The membranes were then washed by PBS-Tween20 
(1mL Tween20 /1L PBS) before incubated with fluorescently-labelled secondary 
antibodies diluted with Odyssey Blocking Buffer (diluted 50:50 in PBST) at dilution 
1:10,000. Mouse-derived primary antibodies were detected using an anti-mouse 
fluorescently-labelled secondary antibody (680nm wavelength) whilst rabbit-derived 
primary antibodies were detected using an anti-rabbit fluorescently-labelled 
secondary antibody (800nm wavelength). By combining a mouse primary and a 
rabbit primary along with their respective secondary antibodies (one of 680nm and 
the other of 800nm), dual-labelled Westerns were obtained. Secondary antibody 
incubation lasted 45min at room temperature in the dark with gentle shaking. The 
membranes were then scanned on the Li-Cor Odyssey scanner, and the fluorescence 
value (integrated intensity, I.I.) corresponded with the detected protein expression 
levels. Α-tubulin (Mouse derived, Abcam, ab7291) was selected as loading control. 
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Primary antibody Working Dilution Source Supplier/Catalogue No. 
Anti-HP1 alpha 1:1000 Rabbit Cell Signaling/2623 
Anti-HP1 beta 1:1000 Rabbit Abcam/ab10478 
Anti-HP1 gamma 1:1000 Rabbit Cell Signaling/2619 
Anti-HDAC1 1:1000 Mouse Cell Signaling/5356 
Anti-HDAC2 1:1000 Rabbit Cell Signaling/2540 
Anti-HDAC3 1:1000 Rabbit Abcam/ab32369 
Anti-HDAC4 1:1000 Rabbit Abcam/ab32534 
Anti-HDAC8 1:1000 Rabbit Abcam/ab39664 
Anti-AMT 1:750 Mouse Abcam 
Anti-pATM 
(Ser1981) 
1:1000 Rabbit Cell signalling/4526 
Anti-ATR 1:1000 Rabbit Abcam/ab2905 
Anti-pATR(Ser428) 1:1000 Rabbit Cell Signaling/2853 
Anti-
pBRCA1(Ser1524) 
1:1000 Rabbit Cell Signaling/9009 
Anti-γH2AX 1:1000 Rabbit Cell Signaling/2577 
Anti-Rad51 (H-92) 1:1000 Rabbit Santa Cruz/sc-8349 
Anti-α-tubulin 1:6000 Mouse Abcam/ab7291 
Anti-β-tubulin 1:6000 Rabbit Abcam/ab6046 
Anti-GAPDH 1:8000 Mouse Abcam/ab8245 
Table 2-1 Primary antibodies used for Western blot analysis. 
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2.9  Preparation of RNA 
Total RNA was extracted from cultured cells using Qiagen Mini RNeasy Kit. Cell 
culture medium was completely aspirated before the cell lysis. Cells (no more than         
1 x 107 cells) were directly lysed by adding 350µl Buffer RLT to the cell-culture dish. 
After that, the lysate was collected by a rubber policeman, pipetted into a 
microcentrifuge tube, and then vortexed to remove cell clumps. 1 volume of 70% 
ethanol was applied to the homogenized lysate. Immediately after pipetting, the 
sample which included any precipitate that might have formed was transferred into 
an RNeasy Mini spin column in a 2ml collection tube, centrifuge at 8000 x g for 15s 
at room temperature. Flow-through was discarded and this step was repeated till the 
entire sample was done. The RNA sample in the column was washed by Buffer RPE 
with centrifugation for 15s at 8000 x g. After washing, the RNeasy Mini spin column 
was transferred to a new 1.5ml collection tube. The total RNA was eluted in 30ul 
RNase-free water by centrifuging for 1 min at 8000 x g. The concentration and 
quality of RNA was assessed by NanoDrop.    
 
2.10  Real time Polymerase chain reaction (PCR) 
1µg of total RNA from each individual sample was reverse transcribed by using the 
QuantiTect Reverse Transcription kit (Qiagen) following the manufacturers’ protocol. 
The contaminating genomic DNA was effectively removed by incubating with 
gDNA Wipeout Buffer (comes with the kit) at 42°C for 2min. After genomic DNA 
elimination the reverse transcription was carried out by adding a master mix prepared 
from Quantiscript Reverse Transcriptase, Quantiscript RT Buffer and RT Primer Mix 
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to the RNA sample. The entire reaction was incubated at 42°C for 15 min and then 
inactivated at 95°C for 3 min. 20µL of cDNA was yielded from 1µg total RNA 
following the reverse transcription.  
cDNA was quantified using Rotorgene (Corbett Research, San Francisco, CA) and 
the QuantiTect SYBR Green system (Qiagen) following the manufacturers’ 
instructions. For PCR reaction, a 13-fold dilution of the above cDNA mixture (10-
fold dilution for standard curve) and a 10-fold dilution of primers HDAC8, β-actin 
(ordered from Qiagen) were used. A 15ul mixture of 7.5µl 2xQuantiTect SYBR 
Green iMaster Mix, 1.5 µL primer mix (0.3 µM), 2.5mM of MgCl2, 1.5 µL cDNA 
was prepared in RNase-free water for the PCR reactions. The standard PCR protocol 
used was as follows: initial activation at 95°C for 15min; 45 cycles of denaturation at 
94°C for 15s; annealing at 56°C for 30s; extension at 72°C for 30s and a final 
extension at 72°C for 5min followed by a melt step from 55°C to 95°C at 0.2°C/s. 
 
2.11  Human sample study population 
Ovarian cancer samples were collected before and after chemotherapy respectively. 
There were 38 pairs remaining for statistical analysis after TMA construction, 
immunostaining, AQUAsition and AQUAnalysis. TMAs were constructed in 
biological triplicates (patient information shown in Table 2.2-2 and full data are 
provided in Table S8). 
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Classification sub-classification patient number % total 
Regimen 
Carboplatin/Paclitaxel 11 29 
Cisplatin 7 18 
Carboplatin 17 45 
Cisplatin/Topotecan 3 8 
Sensitivity 
responsive 19 50 
resistant/refractory 19 50 
FIGO stage 
2A 2 5 
2B 2 5 
2C 2 5 
3(pre FIGO) 4 11 
3A 2 5 
3C 16 42 
4 6 16 
Grade 
2 10 26 
3 27 71 
Histology 
Endometrioid 14 37 
Mucinous 3 8 
Serous papillary 15 39 
mixed Serous/endometrioid 1 3 




Undifferentiated carcinoma 1 3 
Table 2-2 Ovarian cancer Patient information in the TMA used in this study. 
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2.12 Tissue Microarray (TMA) construction 
TMAs consist of paraffin blocks in which as many as up to 1000 tissue cores of 
samples to be tested are assembled in array fashion to allow simultaneous 
histological analysis. A hollow needle is used to sample tissue cores from regions of 
interest in paraffin embedded tissues, which includes clinical biopsies or tumour 
samples. The extracted tissues are then embedded into a recipient paraffin block in a 
precisely spaced array pattern for further analysis.  
For this thesis, the TMAs (constructed by In Hwa Um; University of Edinburgh) 
were made according to protocols established in our lab. In brief, 0.6 mm tissue 
cores were removed from each ‘donor’ paraffin-embedded tumour block and then 
precisely mounted into new ‘recipient’ paraffin blocks (Figure2.2-1) to form the 
TMAs in certain orientation, after which 4µm of formalin-fixed, paraffin embedded 
sections were cut from each TMA block on to microscope slides.  
                              
Figure 2.12-1 Representative picture for a TMA block.  The spot on paraffin block were from 
each ‘donor’ paraffin-embedded tumour block. The TMAs were constructed in certain 
orientation so that every core will be easily distinguished to link to relative tumour information. 
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2.13  Immunohistochemistry (IHC) 
This assay was performed for antibody optimization. 4µm of formalin-fixed, paraffin 
embedded sections cut from each TMA block were deparaffinised in xylene for 5min 
and rehydrated in 99%, 99%, 80% and 50% ethanol for 2min, respectively. Antigen 
retrieval was then achieved by treating slides with microwave pressure cooking in 
0.15mM Sodium Citrate, pH6.0 buffer or Tris-EDTA, pH9.0 for 5min. After the 
antigen retrieval, slides were left at room temperature for at least 20min to cool down. 
Cooled slides were rinsed in 0.05% phosphate buffered saline (PBS, OXOID, 
#BR0014G)-Tween (Tween20, BIO-RAD, #170-6531) (PBS-T) twice for 5min 
followed by blocking in 3% hydrogen peroxide (in order to block endogenous 
peroxidase activity) and serum free protein block (Dako, #X0909) for 10min each in 
staining trays. After rinsing in PBS-T 2 x 5min, the blocking slides were then 
incubated with primary antibody diluted using Dako antibody diluent (Dako, 
#S0809). The optimal dilution factor of each antibody was determined by our own 
laboratory. Table 2.2-3 lists information of all primary antibodies used in this assay. 
Target primary antibodies were incubated for either 1 h at room temperature or 
overnight at 4°C according to the antibody optimization and validation data and then 
rinsed again with PBS-T.  In order to stain sections the Dako REAL EnvisonTM 
Detection system (Dako, #K5007), which consists of Envision™/HRP solution, 
diaminobenzidine (DAB chromogen) and substrate buffer containing hydrogen 
peroxide, was applied to the primary antibody-treated samples. In brief, sections 
were incubated at room temperature with Dako Envision Envision™/HRP solution 
which comprised of a dextran backbone coupled to multiple peroxidase (HRP) 
molecules and a mixture of secondary mouse antibody molecules for 30min, rinsed 
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with PBS-T, and then incubated with DAB substrate in DAB buffer diluted 1:50 for 
10min to visualise the colour develops. Following the staining step, sections were 
counterstained in haematoxylin for 30s and then rinsed with Scott’s tap substitute. 
After that, sections were dehydrated by going through graded alcohols to xylene. As 
described before sections were treated for 2min in each alcohol solution and 5min in 
each xylene. Finally dehydrated sections were mounted with glass coverslip using 
DPX mountant. By using negative controls, different antigen retrieval methods, and 
different antibody concentration and incubation methods, optimum conditions for 
each antibody and each tissue were evaluated on the following aspects: intensity of 
positive staining (with scoring ranging from 3 points for maximum intensity positive 
staining to 0 points for no positive staining), lack of non-specific background (with 
scoring ranging from 3 points for no background staining to 0 points for intense 
widespread background staining), and signal to noise ratio (with scoring ranging 
from 3 points with no non-specific staining, to 0 points for no positivity but strong 











HP1$alpha$ Breast$ 1:50,$1:150,$1:300$ Rabbit$ IgG$ Cell$Signaling$ 1:50$
HP1$alpha$$ Ovary$ 1:50,$1:100$ Rabbit$ IgG$ Cell$Signaling$$ 1:100$
HP1$beta$ Breast$ 1:50,$1:150,$1:300$ Rabbit$ IgG$ Abcam$ 1:100$
HP1$beta$ Ovary$ 1:100,$1:150$ Rabbit$ IgG$ Abcam$ 1:150$
HP1$gamma$ Breast$ 1:100,$1:250,$1:500$ Rabbit$ IgG$ Cell$Signaling$ 1:250$
HP1$gamma$ Ovary$ $1:250,$1:400$ Rabbit$ IgG$ Cell$Signaling$ 1:400$
HDAC1$ Ovary$ $1:100,$1:200,$1:400$ Mouse$ IgG$ Cell$Signaling$ 1:200$
HDAC2$ Ovary$ $1:25,$1:50,$1:100,$1:200$ Mouse$ IgG$ Cell$Signaling$ 1:25$
Table 2-3 Primary antibodies used for antibody optimization in immunohistochemistry. 
 
2.14  Immunofluorescence (IF) on TMAs 
This assay was performed with the optimized condition for each target protein as 
listed in Table 2.2-4. 4µm of sample sections were deparaffinised in xylene for 5min 
and rehydrated in 99%, 80% and 50% ethanol for 2min, respectively. For antigen 
retrieval, sections were treated with 0.15mM Sodium Citrate, pH6.0 buffer or Tris 
EDTA, pH9.0 using a microwave pressure cooker for 5min. Sections were then left 
at the room temperature for at least 20min followed by rinsing in 0.05% PBST, 
blocking in 3% hydrogen peroxide and serum free protein block (Dako, #X0909), 
10min each. After blocking slides were then incubated with primary antibodies 
diluted with optimal dilution in second primary antibody (Mouse anti- cytokeratin, 
Invitrogen, #18-0132) diluted in Dako antibody diluents with 1:25 dilution either for 
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1h at room temperature or overnight at 4°C. Sections were then rinsed in 0.05% 
PBST 3 times 5min each followed by incubation with secondary antibodies for 1h at 
room temperature, which included a 1:25 dilution of the goat anti-mouse Alexa 555 
antibody (Invitrogen, #A21422). After rinsing in 0.05% PBST 3 × 5min, sections 
were transferred from the sequenza to the humidity chamber and incubated with 
target signal amplification diluents and the Cy5 Tyramide at 1:50 concentration in 
the dark for 10min at room temperature to allow the visualisation of target protein. 
Slides were rinsed again in 0.05% PBST 3 × 5min, dehydrated in 80% ethanol for 
1min and air dried in the dark. For counterstaining and coverslipping, 45ul of 
Prolong Gold anti-fade reagent with DAPI (Invitrogen, P36931), nuclear 
visualisation media was applied to the 20 × 26mm coverslip, which was then placed 
over the tissue. Mounted slides were left in the dark overnight in order to dry, 
secured with nail polish to ensure long term preservation and kept in a 4°C 
refrigerator. The antibodies used for IHC and IF were validated by western blotting. 
Blots were required to show a single band at the correct molecular weight. These 
validation experiments were performed either by myself or other individuals working 















HP1$alpha$ Breast$ 1:50$ Microwave + 
pressure cooking 
Sodium Citrate Over night at 4°C Cell$Signaling$
HP1$alpha$$ Ovary$ 1:100$ Microwave + 
pressure cooking 
Sodium Citrate Over night at 4°C Cell$Signaling$$
HP1$beta$ Breast$ 1:100$ Microwave + 
pressure cooking 
Sodium Citrate One hour at room 
temperature 
Abcam$
HP1$beta$ Ovary$ 1:150$ Microwave + 
pressure cooking 
Sodium Citrate One hour at room 
temperature 
Abcam$
HP1$gamma$ Breast$ 1:250$ Microwave + 
pressure cooking 
Sodium citrate Over night at 4°C Cell$Signaling$
HP1$gamma$ Ovary$ 1:400$ Microwave + 
pressure cooking 
Sodium citrate Over night at 4°C Cell$Signaling$
HDAC8$ Breast$ 1:100$ Microwave + 
pressure cooking 
TE Tris One hour at room 
temperature 
Abcam$
HDAC8$ Ovary$ 1:100$ Microwave + 
pressure cooking 
TE Tris One hour at room 
temperature 
Abcam$
HDAC1$ Ovary$ 1:200$ Microwave + 
pressure cooking 
Sodium citrate One hour at room 
temperature 
Cell$Signaling$
HDAC1$ Ovary$ 1:25$ Microwave + 
pressure cooking 
Sodium citrate Over night at 4°C Cell$Signaling$
Aurora$A$ Ovary$ 1:25$ Microwave + 
pressure cooking 
Sodium citrate Over night at 4°C Cell$Signaling$
Aurora$A$ Ovary$ 1:400$ Microwave + 
pressure cooking 
Sodium citrate One hour at room 
temperature 
Abcam$
Geminin$ Ovary$ 1:800$ Microwave + 
pressure cooking 
Sodium citrate One hour at room 
temperature 
Abcam$
Table 2-4| Antibodies used in immunofluorescence.  
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2.15  Automated Quantitative Analysis (AQUA) of protein 
expression 
The IF result was analysed using the automated quantitative analysis (AQUA) 
system. After the counterstaining and cover-slipping steps, the slides were imaged on 
the HistoRx PM- 2000™ instrument (Camp, Chung et al. 2002) by an automated 
spot capturing system (Figure 2.2-2).  
 
Figure 2.15-1 TMA Spot finding (Red spot-inner spots, Green-outer line spots, Blue-four corner 
spots). 
 
Images were visualised by using AQUAsition software at 20 x magnifications via 
DAPI, CY3 and CY5 channels (Figure2.2-3). Afterwards, high-resolution images 
obtained were analysed using the AQUA® technology platform. For each 
immunofluorescence image, AQUAnalysis software evaluated the quantity (in 
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AQUA units=Au) of target protein expression (through Cy-5-thymide) within the 
cytoplasm (identified by cytokeratin) and nuclei (4,6-Diamidino-2-phenylindole, 








Figure 2.15-2 The process of compartmentalisation in AQUA analysis. DAPI counterstaining in 
blue was used to identify nuclear (top left), cytokeratin staining in green was to separate 
tumour cells and normal epithelial cells (top right), Cy-5-thymide in red detects target protein 
(bottom left) and compartmentalised analysis of tissue sections (bottom right). 
 
Before obtaining the final AQUA scores, each image was examined to exclude 
imaging faults and normal tissue, thus target protein expression was scored only in 
invasive cancers. In addition, cores containing epithelium <5% of their total area 
were automatically excluded by the software to make sure that tumours were 
appropriately represented for AQUA scoring (Camp et al., 2002). An in-house 
quality control slide was used for control to ensure the proper staining each time 
(Figure 2.2-4). The final normalised AQUA score detecting the fluorescence 
correlates with the expression level of target protein. 
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Cy3                                                                 Cy5 
                 
DAPI 
 
Figure 2.15-3 An example of our in-house quality control slide and the process of validation of 
staining for each control. There are three different groups of tissue cores on the control slide 
(top figure), and a PAP Pen was used to separate groups to provide a hydrophobic barrier for 
different antibody probing. Cytokeratin TMA visualised in the Cy3 channel was used to check 
the quality of the tumour mask staining, while a positive control TMA was used to ensure the 
quality of each antibody used. Finally, the negative control TMA, without any primary antibody 
added, was used to show any non-specific binding as a result of unsuccessful blocking. 
 
2.16  Cell cycle analysis 
Cells were harvested and plated as described for western blotting. At each time point, 
cells were trypsinised and then transferred to 5 mL BD Falcon tubes (BD 
Biosciences). Citrate buffer (Trisodium Citrate (301287F, BDH Laboratory Supplies), 
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Sigma) and 2mL Nonidet NP40 (N3516, Sigma) in 2000mL distilled water, pH7.6) 
was added as the stock solution after centrifuge.  Then the following solutions were 
added incubating in sequence before running: 450uL solution A (0.003% Trypsin 
Type IX-S (T0303, Sigma) in Citrate buffer pH7.6) for 2 minutes, solution B (0.05% 
Trypsin Inhibitor (T9253, Sigma) and 0.01% RNAse A (R4875, Sigma) in Citrate 
buffer pH7.6) for 10 minutes, and solution C (0.0416% Propidium Iodide (81845, 
Sigma) and 0.1% Spermine Tetrahydrochloride (S2876, Sigma) in 500mL Citrate 
buffer pH7.6) for 10 minutes in the dark. Flow cytometric analysis for samples was 
then performed using a BD FACSAriaII SORP (Becton Dickinson). The 488nm laser 
was used for measuring forward scatter, side scatter, and PI fluorescence (685/35 
bandpass filter). BD FACSDiva software (Becton Dickinson, Version 6.1.2) was 
used for instrument control and Flowjo software (Version 7.6.5) for Data analysis.   
 
2.17 Detection of apoptosis by annexin-V assay 
Cells were harvested in log phase and plated into 60mm petri dishes and incubated 
for 72h with or without siRNA transfection. After treatment with drug, cell apoptosis 
was detected at 24h by using the TACS Annexin V-FITC Kits (R &D Systems) 
according to the manufacturer’s protocol. Cells were collected and washed with ice-
cold PBS once, and then 100uL Annexin V Incubation reagent (10uL 10x Binding 
Buffer, 10uL Propidium Iodide (PI), 1uL Annexin V- FITC, and 79uL Distilled 
water) was added into each sample. 400uL 1x Binding Buffer was then applied to 
each sample after 15 min incubation in the dark. Negative stained, PI stained only, 
Annexin V- FITC stained only were prepared as controls. The apoptotic cells were 
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detected by BD FACSAriaII SORP (Becton Dickinson). BD FACSDiva software 
(Becton Dickinson, Version 6.1.2) was used for instrument control and Data analysis 
were performed by Flowjo 7.6.5. 
 
2.18  V250 Proteomic analysis 
This proteomic microarray was performed by Eurogentec. Briefly, 120 signalling 
proteins and their phosphorylated (activated) forms were selected to detect their 
expression level change among 12 ovarian cell lines (OVCAR3, OVCAR4, 
OVCAR5, SKOV3, OAW42, PE01, PE04, TOV112D, TOV21G, 41M, 59M, and 
ES2). Each array was constructed by one cell line; every six spots were six replicates 
for one protein detection. Fluorescence of the second antibody detected was 
associated with the expression level of relative protein. 
 
2.19 Immunofluorescence assay on cell lines 
Cells were grown with or without treatment on autoclaved coverglasses (thickness 
No.1, VWR, 631-0149) and fixed by 4% paraformaldehyde for 15 minutes. After 
washing with PBS-0.05% TWEEN20 for 10 minutes and blocked in DAKO serum-
free blocking buffer (X0909), slides or cover glasses are incubated with primary 
antibodies for one hour at room temperature. Secondary Goat anti Rabbit Alexa 488 
(1:400) or anti Mouse Alexa 654 (1:400) and Gold anti-fade reagent with DAPI 
(Invitrogen, P36931) were used to detect the target proteins and nuclear compartment 
respectively.  
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2.20 Nuclear texture analysis 
Confocal images were obtained using a Nikon A1R Confocal Microscope and 
images were obtained via NIS viewer software. Cells were grown in chambered 
slides for specific period and fixed by 4% formalin in PBS for 10 minutes. After 
washing with PBS-0.05% TWEEN20 three times, slides were counterstained with 
anti-fade reagent with DAPI (Invitrogen, P36931). The nuclear texture was then 
analysed with Image J software.  Briefly, after 8-bit images were input, any unclear 
or non-tumour areas were cropped and clearly focused areas with tumour cells were 
selected. Proper thresholds for nuclear size were set up and individual nuclear was 
then selected within region of interest (ROI) (Figure 2.2-2). Nucleus counters and 
GLCM (Gray-Level Co-Occurrence) manager plugins were performed for each 
image, and 5 parameters associated with texture: correlation, contrast, angular 
second moment, inverse different moment, and entropy were obtained (Table 2.2-5).  
           






chromatin patterns  
homogeneity of 
chromatin patterns  
contrast of chromatin 
patterns  
Correlation (+)  
sum variance 
variance  
angular second moment (+)  
Entropy (-)  
sum entropy 
run percentage  
difference entropy 
difference variance 
inverse difference moment (-)  
Contrast (+)  
Table 2-5 Common morphometric parameters in nuclear texture study.  The ones in red are 
from output in Image J, and +/- indicated their positive or negative correlation with each related 
kind of chromatin pattern (heterogeneity, homogeneity, or contrast).   
 
2.21 Quantitative analysis of γH2AX foci formation in cells 
Cells were grown and stained as described in 2.2.19, and the primary antibody anti-
phosphohistone H2AX (ser139, γH2AX) was from Millipore (cat. 05-636). After 
slides were mounted with DAPI and air-dried, the cells were visualised by 
BriteMAC or MacRd microscope in the Imaging Suite of MRC Human Genetics 
Unit in Western General Hospital. The nuclear images were taken by IPLab software 
under single filters for each channel with the same exposure setting for each set of 
experiment. For each slide, more that 100 nuclei were counted for the foci formation 
analysis. 
After immunofluorescence images were acquired, the number of γH2AX foci in each 
nucleus was counted by the PZ Foci EZ plugin in ImageJ software using the 
instructions on the website (available at www.pzfociez.com). For short, a nuclear 
mask, which defined the regions of interest (ROI, i.e. nuclear outlines), was made 
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first for each channel, and then the foci number was counted automatically in the 
proper channel within the ROI defined. Several background threshold and noise 
tolerance may be tried to get the optimum result. 
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2.22 Statistical analysis 
To be able to compare our results to that of the V250 arrays, we calculated the ratio 
of non-phospho form over phospho form of each antibody. Student’s t-test was used 
in comparison of two independent samples. One-way ANOVA followed by Tukey 
HSD post HOC test was used to conduct multiple comparisons of groups with equal 
variance. Pearson correlation analysis was  performed in the association detection for 
IF result. Wilcoxon signed-rank test is used to compare target protein expression 
differences between the pre- and post-treatment samples from patients Man-whitney 




3.1 Quantifiable changes in nuclear structure during 
chemotherapy in ovarian cancer cells 
In order to robustly measure the nuclear morphological changes described, nuclear 
texture was first analysed using microscopy and ImageJ image analysis software. 
The condensation and distribution of chromatin in the nucleus has been demonstrated 
by nuclear texture changes in image cytometric studies (Yatouji, El-Khoury et al. 
2007). The higher-order chromatin structure was quantified through nuclear texture 
analysis using digital images to get computational analysis even for subtle 
differences to the naked eyes.  
 
3.1.1 Study method development for texture analysis 
As described in the Materials and Methods, cells grown on coverslips were treated 
with cisplatin or ionising radiation at different doses, and incubated for 0h, 6h, 12h, 
and 24h. After DAPI staining and imaging, cellular nuclear texture was 
quantitatively analysed using the widely available computational image analysis 









Figure 3.1-1 Microscope image acquisition procedures for the study of nuclear texture. For 
detailed methodology, refer to Material and Methods.    
 
The texture of an image can be evaluated using mathematical formulae based on the 
‘grey level co-occurrence matrix’ (GLCM) (Alvarenga, Pereira et al. 2007). Haralick 
et al. described in detail how to turn the pixel data from greyscale images into 
matrices to represent an image’s texture. This represents a second order texture 
calculation that considers the distance and angle relationship between groups of two 
pixels in the original greyscale image under the same intensity of grey pixels within a 
defined area. Since the reporting of the formulae, texture analysis has been applied in 
C. Nuclear texture analysis in ImageJ with GLCM (Gray-Level Co-
Occurrence) manager plugins  
Cisplatin)(1.5uM,)3uM,)6uM) 
0h,)6h,)12h,)24h 
B. DAPI staining 
A. PEO1 cells grown 






a range of studies including analysis of nuclear texture for a number of purposes, 
such as differentiating between benign and malignant cancers (Murata, Mochizuki et 
al. 2002), and examining apoptotic cells (Pantic et al., 2012). After images were 
imported into ImageJ, five texture parameters were generated from the GLCM 
manager plugins for each selected nucleus within the images, namely correlation, 
angular second moment (ASM), entropy, inverse different moment (IDM), and 
contrast.  
 
Figure 3.1-2 Examples of some common textures: tree bark (A), polished granite (B), glass (C), 
carpet (D), corduroy (E), and knit (F).  The textures of these images are becoming more regular, 




The five measured parameters are essential in order to fully describe the texture 
within a defined region. As explained in the literature (Murata, Mochizuki et al. 
2002; Sacile, Montaldo et al. 2003), the texture features can be either positively or 
negatively correlated with several chromatin patterns (homogeneity, heterogeneity, 
and contrast) as a description of the arrangement of the surface of nuclei (Table 3.1-
1):  
• ASM provides a strong measurement of uniformity or smoothness of an 
image and positively correlates with overall homogeneity of chromatin 
patterns.  
• Entropy, which effectively measures the overall disorder of patterns, 
correlates negatively with overall homogeneity. 
• IDM measures the local homogeneity of an ROI and is affected by the 
homogeneity of the image. Non-homogeneous areas normally result in low 
IDM values. Thus it is described as ‘contrast’ of chromatin patterns. 
• Contrast measures the local variability of patterns, local intensity variation, 
and will favour contributions from pixels away from the diagonal. 
• Correlation calculates the grey-level linear dependency of the image, and 







chromatin patterns  
Homogeneity of 
chromatin patterns  
Contrast of chromatin 
patterns  





Contrast (+)  
Table 3-1 The parameters generated by the GLCM manager plugins in ImageJ and their 
association with different chromatin patterns: heterogeneity, homogeneity, and contrast. The (-) 
and (+) in red indicates the positive and negative correlation with each related kind of 
chromatin pattern, respectively.  
 








A" 0.0104" 97.6683" 0.000525" 0.2086" 6.8727"
B" 0.0044" 143.1648" 0.000552" 0.1959" 7.1211"
 
Figure 3.1-3 Example of nuclear texture analysis and parameter acquirement. Image and data 
are from ovarian cancer xenografts without (A) or with (B) carboplatin treatment, and samples 
were stained with DAPI.   
 
Illustrations are shown in Figure 3.1-2 to demonstrate the texture variation among 
different original images, and an example is displayed in Figure 3.1-3 showing how 
those parameters can reflect the chromatin conformation seen under microscope.  
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3.1.2 Nuclear texture analysis in DNA damage-based therapies in vivo 
and in vitro 
Having defined a robust method of measurement for nuclear texture features, I 
applied the method to detect nuclear texture changes in both the PEO1 ovarian 
cancer cell line and the xenograft model after treatment with DNA damage-based 
therapies (cisplatin, radiation, or carboplatin). 
 
3.1.2.1  Measurement of nuclear texture changes in vitro upon 
cisplatin/radiation treatment 
 
After 24h treatment with 6μM cisplatin or 6Gy radiation, (similar to several previous 
studies) (Petru, Sevin et al. 1997; Arafa el, Zhu et al. 2009; Cooke, Ng et al. 2010; 
Liang, Kong et al. 2012), the image texture parameters all changed in a positive or 
negative direction compared with the untreated group. As shown in Figure 3.1-2, 
similar results were observed after cells were treated with either cisplatin or radiation. 
ASM, correlation, and IDM all decreased after treatment of cisplatin/radiation by 
20%/23%, 25%/49%, and15%/11% respectively, while entropy and contrast 
increased by 6%/8% and 15%/11%, indicating the texture of those nuclear images 




Figure 3.1-4 Changes in features describing nuclear texture in PEO1 cells after radiation or 
cisplatin treatment. PEO1 cells were grown on coverslips and treated with ionising radiation 
(6Gy) or cisplatin (6uM) for 24h, and nuclei were stained with DAPI for visualisation using a 
fluorescence microscope. At least 100 nuclei were included for each experiment. Nuclear 
texture was analysed by measuring five texture parameters (angular second moment, 
correlation, entropy, inverse different moment, and contrast) in the ImageJ software. Data are 




Using the method described previously, the changes in parameters were described in 
terms of nuclear texture (Table 3.1-2). A decreased correlation indicated a more 
heterogeneous chromatin pattern; in contrast, decreased ASM and increased entropy 
suggested less homogeneity in the chromatin pattern The opposite changes in IDM 
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Contrast (+)  
Cisplatin 6mM/ 
Radiation 6Gy 
              
 
 
Table 3-2 Changes in chromatin patterns in PEO1 cells after cisplatin (6uM) or radiation (6Gy) 
treatment for 24h, measured by parameters describing nuclear texture using ImageJ. The (+) 
and (-) represent positive and negative correlations with each type of chromatin pattern, 
respectively, and the arrows indicate the direction of change for each pattern. 
 
By quantitatively measuring the chromatin patterns based on nuclear texture, we 
demonstrated an increase in heterogeneity and contrast of chromatin, and decreased 
homogeneity in the nuclei of these cells after DNA damage-induced treatment, such 
as cisplatin and radiation, which is consistent with the observations viewed using 
light microscopy.  
 
3.1.2.2 Measurement of nuclear texture changes in response to 
carboplatin in vivo 
As the results of the in vitro study demonstrated the existence of changes in higher 
order chromatin organization in ovarian cancer cells after either cisplatin or radiation 
treatment, we sought to identify whether similar changes in nuclear texture exist in 
vivo. 
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As described in the Materials and Methods, the ovarian tumour tissue samples from 
the OV1002 xenograft model, already developed in our laboratory, were analysed. 
After treatment with carboplatin, ovarian tumours were collected on day 0, 1, 2, 4, 7, 
and 14 after a single dose treatment. Samples were then cut and spotted on a tissue 
microarray slide for further study. 
In order to obtain an overall qualitative view of the nuclear organization in these 
tumour samples, an H&E stained TMA slide was first assessed. As shown in Figure 
3.1-3, the nuclear morphology in most untreated tumours was strongly stained and 
homogeneous (Figure 3.1-3 A-F), while lighter staining and greater heterogeneity 
was observed in the nuclei of samples after carboplatin treatment (Figure 3.1-3 G-M). 
This observation argues against the features seen in clinical specimens being purely 
artefactual, since the fresh staining is performed on samples treated for a short term 
period (0-14 days) and collected at the same time for untreated and treated groups on 






         
 
         
 








         
         
 








Figure 3.1-5 Representative images from H&E stained OV1002 ovarian tumour samples before 
(A-F) and after (G-M) carboplatin treatment in vivo. Female adult CD-1 nude mice housed in 
IVCs (individually ventilated cages) were treated with Carboplatin (50 mg/kg i.p.) on Day 0, and 
tumour samples were collected on Day 0, 1, 2, 4, 7, and 14 after treatment. H&E staining was 
performed on TMA slides, and the images were acquired using a camera mounted on a light 
microscope under 40X magnification. 
Similar to the in vitro study, we analyzed the nuclear texture using ImageJ to 
quantitate the changes in chromatin pattern. The number of nuclei analysed per 
sample ranged from 16 to 213 (average 103), and the number of mean values per 
group ranged from 13 to 21 (average 16). See Table S1 in the Supplement for a 
summary of these statistics. 
As is shown in Figure 3.1-4, the distribution of the texture parameters in samples 
after carboplatin treatment was altered compared to control groups, while the most 
significant effects of single dose carboplatin on xenografts were typically seen two 
days after treatment, with two parameters (entropy and IDM) showing statistically 
significant difference (p=0.034 and 0.008, respectively; Figure3.1-4), indicating that 



















Figure 3.1-6 Nuclear texture parameter analysis in xenografts with and without carboplatin 
treatment on Day 2. Data for each spot represents the average value of each single sample from 
triplicate TMAs, and the number of nuclei analysed per sample ranged from 16 to 213 (average 


































































































































The observed changes in the parameters were very similar to the changes seen in 
vitro. As shown in Table 3.1-3, the homogeneity of the chromatin patterns decreased, 
as shown by a significant increase in entropy after treatment (0.034), compared to 
control. The contrast of the chromatin patterns increased with inverse difference 


























Table 3-3 Changes in chromatin patterns in xenograft samples after carboplatin treatment on 
day 2, measured by parameters representing nuclear texture using ImageJ. The (+) and (-) 
represent positive and negative correlation with each type of chromatin pattern, respectively. 
Arrows indicate the direction of alteration for each pattern. 
 
The quantitative measurements support the qualitative observation in changes in 
nuclear morphology using H&E. Only two parameters were statistically significant; 
this might be due to the small sample size (six or seven samples each group), or due 
to heterogeneity of the tumour tissue since only a proportion of the tissue is sampled 
using TMA cores. As shown in Figure 3.1-3 E and F, some nuclei in tumors without 
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treatment showed condensed structure similar to those after treatment, although the 





























In vivo Carboplatin 
(Day2) 
-   
Table 3-4 Summary of changes in chromatin patterns in vitro and in vivo after DNA damage- 
based therapy, measured by parameters representing nuclear texture using ImageJ. The (+) and 
(-) represent positive and negative correlation with each type of chromatin pattern, respectively. 
The arrows indicate the direction of alteration for each pattern. 
 
In summary, the trend in alterations for each chromatin pattern was comparable both 
in vitro and in vivo, and the chromatin tended to be more condensed after those 
treatments. Thus these data strongly support our hypothesis that nuclear 
morphological changes occur after certain cellular damage. 
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3.2 Molecular effect of cisplatin treatment on chromatin patterns 
and HDAC expression in ovarian cancer cells 
 
Since morphological changes were observed and could be quantified during DNA 
damage-based therapy, this raised questions about the biological cause of these 
changes and the cellular events occurring in the surviving cells during treatment. To 
better understand the processes occurring in the nuclei associated with the chromatin 
pattern changes during treatment, the well-studied ovarian cancer cell lines PEO1 
and PEO4 cells were chosen for further in vitro studies. 
 
3.2.1 Characterization of the cell line models, including cisplatin 
responsiveness 
 
As described in the original report describing the original ovarian adenocarcinoma 
cell lines (Langdon, Lawrie et al. 1988), PEO1 and PEO4 cells were derived from 
peritoneal ascites obtained from the same patient with poorly differentiated serous 
adenocarcinoma at different stages of therapy. PEO1 cells were collected after cis-
platinum (CDDP), 5-fluorouracil (5-FU), and chlorambucil treatment and showed 
responsiveness to treatment after 22 months (Ng, Cooke et al. 2012). However, 
PEO4 cells were established when clinical resistance was exhibited to those agents 
ten months later. The study also detailed other characteristics of these cell lines, 
including growth characteristics, modal chromosome numbers, and antigen 
expression. The different cisplatin sensitivity between the cell lines has also been 
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studied and suggested to be due to a BRCA2 deficiency in PEO1 cells and a 
secondary mutation to restore BRCA2 proficiency in PEO4 cells (Sakai, Swisher et 
al. 2009). 
 
3.2.1.1  Morphological characteristics of PEO1 and PEO4 cells 
The morphology of these two cell lines was first examined in cells grown in 
monolayers after settling in dishes, and subtle differences were visible by light 
microscopy. Although both cell lines tended to grow as islands of uniform polygonal 
cells, PEO4 cells formed smaller clusters when compared to PEO1 cells. 
Furthermore, the growth rate of PEO4 cells was much slower. 
 
A. PEO1                                                       B. PEO4  
   
Figure 3.2-1 Images of live PEO1 and PEO4 cells under the light microscope. PEO1 and PEO4 
cells were seeded and grown on plastic cell culture dishes for 24-72h; typical images were 
taken using the light microscope to compare their morphological characteristics.   
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3.2.1.2 Cisplatin sensitivity of PEO1 and PEO4 cells 
 
To address the sensitivity to cisplatin treatment and demonstrate the PEO1/PEO4 cell 
line pair as an appropriate model to investigate resistance during chemotherapy, SRB 
assays were performed to confirm the growth characteristics of these two cell lines 
with cisplatin treatment. Four concentrations of cisplatin from a serial dilution were 
applied to the cells, and cell density was detected on each day after treatment from 0 
to 5 days. As shown in Figure 3.2-2, cell number was reduced in both PEO1 (Figure 
3.2-2A) and PEO4 cell lines (Figure 3.2-2B) after cisplatin treatment compared to 
the control group. At 12uM of cisplatin on day 5, the cell number in the treated group 
was only 10% of control group in PEO1 cells, and 29% in PEO4 cells. With 
treatment using different concentrations of cisplatin and periods of incubation, it was 
clearly demonstrated that this inhibitory effect of cisplatin was both time- and dose-
dependent.  
The sensitivity to cisplatin was compared between these two cell lines on day five 
(Figure 3.2-2C). The greatest differential inhibition was at a concentration of 6uM 








Figure 3.2-2 The effect of Cisplatin treatment on cell number in PEO1 (A) and PEO4 (B) cell lines 
using the SRB assay. PEO4 cells were less sensitive to cisplatin treatment compared to PEO1 
cells (C). Cells were seeded and treated as described previously. O.D. values were measured on 
days 0 to 5. Data were plotted as a mean of O.D values +/- SD from three repeated experiments, 
and each experiment was carried out using six replicate samples. SD was calculated from 
averaged O.D values for each biological replicate (n=3). Statistical significance noted for 























































3.2.2 Effect of the HDAC inhibitor TSA on cell growth of PEO1 and 
PEO4 cells 
We speculated that the changes in higher order chromatin structure were associated 
with histone deacetylation, and HDACs are suggested to contribute to the mechanism 
of ovarian cancer resistance and its development. To further understand the effects 
that HDACs have on ovarian cancer cell growth, the SRB assay was performed using 
an HDAC inhibitor, Trichostatin A (TSA), which inhibits the class I and II 
mammalian histone deacetylase (HDAC) families of enzymes. TSA is one of the 
hydroxamic acid-derived compounds and is regarded as a classical HDAC inhibitor, 
which has been reported to produce growth inhibition and induce apoptosis in vitro 
(Chen, Chen et al. 2004).   
3.2.2.1 Cell growth inhibition with TSA treatment alone in PEO1 and 
PEO4 cell lines  
This assay was used to obtain a quantitative measure of cell number after treatment 
with TSA. A two-fold dilution series of TSA from 320nM to 20nM was applied to 
PEO1 and PEO4 cells, and the cell density of both cell lines detected on each day 
from day 0 to day 5 after treatment. Similar to the result shown for cisplatin, this 
HDAC inhibitor also showed an inhibitory effect on cell number in both sensitive 
(PEO1) and relatively resistant (PEO4) cells in a time and dose dependent manner 
(Figure 3.2-3A and Figure 3.2-3B). Furthermore, by comparing PEO1 and PEO4 
data, the inhibitory effect was significantly greater in PEO1 cells compared with 
PEO4 cells (Figure 3.2-3C). This indicated HDAC proteins might be involved in cell 








Figure 3.2-3 The effect of the HDAC protein inhibitor TSA on the growth rate of (A) PEO1 cells, 
and (B) PEO4 cells. All cells were incubated for 72h after seeding, and treated with or without 
TSA from 20nM to 320nM in a two-fold dilution series. O.D. values were measured on days 0, 1, 
2, 3, 4, 5, and 6. The TSA inhibition rate between the two cell lines was plotted from the data on 
day 5 compared to control group. Data were plotted as a mean of O.D values +/- SD from three 
repeated experiments, and each experiment was carried out using six replicate samples. SD 
was calculated from averaged O.D values for each biological replicate (n=3).  *P<0.05, 

























































3.2.2.2 Effect of combination treatment with TSA and cisplatin on cell 
number in PEO1 and PEO4 cells 
Since both cisplatin and TSA were inhibitory to PEO1 and PEO4 cells, we next 
investigated whether there were additive effects when cells were treated with a 
combination of both drugs. Unsurprisingly, after being treated with both cisplatin 
and TSA, cell numbers in both PEO1 (Figure3.2-4A) and PEO4 (Figure3.2-4B) cell 
lines were additionally reduced compared with each individual treatment alone.  
These further reductions were obvious after three (PEO1) or four (PEO4) days of 
treatment, and remained at the lowest OD level during the time course treatment.  
Parallel to the analysis performed on TSA-only treatment, we compared the 
inhibitory effect of each group on day five (Figure3.2-4C). Cell numbers in both cell 
lines were significantly inhibited with the combination treatment of cisplatin and 
TSA (p<0.001). This result shows that the inhibitory effects of TSA and cisplatin on 
cell number occur in both sensitive and resistant cell lines, suggesting that HDAC 
proteins have role on tumor cell growth and an impact on modulating a cancer cell’s 
susceptibility to DNA damage-based therapy. Notably, although TSA showed 
statistically significant inhibitory effect on PEO1 cells, the effect of TSA during this 
experiment set indicate a possible opposite result that PEO4 seems more sensitive to 
TSA inhibition. There are several considerations: firstly, the previous TSA 
experiment apparently demonstrated a statistically significant difference, but the 
absolute difference is actually very small, possibly suggesting minor different effects 
of TSA on between PEO1 and PEO4 cells. Secondly, to make the expected low cell 
density detectable after combined TSA and cisplatin treatment, the initial cell 
number plated was enhanced, indicated by a higher O.D. value in Figure 3.2-4, 
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which implies PEO1 and PEO4 might response dynamically to TSA during their 








Figure 3.2-4 The effect of combination treatment of cisplatin and the HDAC protein inhibitor 
TSA on the growth rate of PEO1 cells (A), and PEO4 cells (B). All cells were incubated for 72h 
after seeding, and treated with TSA (100nM), cisplatin (6µM) to 320nM by two-fold dilution. O.D 
values were measured on days 0, 1, 2, 3, 4, 5, and 6. The cell lines were compared using the 
data on day 5 (c). Data were plotted as a mean of O.D values +/- SD from three repeated 
experiments, and each experiment was carried out using six replicate samples. SD was 
calculated from averaged O.D values for each biological replicate (n=3). One-way ANOVA 
followed by Tukey HSD Post Hoc test was performed between groups for statistical analysis 



























































These data indicate that HDACs have a role in cancer cell growth, and also support 
the current view that HDACs are potential targets during chemotherapy in cancer. By 
linking to their roles in chromatin structure formation discussed previously, these 
results provide some evidence for further investigation of the roles of HDACs in 
nuclear morphological change during DNA damage-based treatment in cancers. 
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3.2.3 Expression induction of HDAC and HP1 after cisplatin treatment 
in cells 
We next evaluated the effect of cisplatin treatment on the expression of HDAC 
proteins in PEO1 and PEO4 cells. Since some studies have demonstrated a role for 
HDACs in mediating condensed or open chromatin structure, we also evaluated 
chromatin formation during this process by using the HP1 heterochromatin markers. 
Thus we examined the expression of HDAC and HP1 using several complementary 
methodologies, namely protein expression level, cellular immunostaining, and 
mRNA levels.  
3.2.3.1 Protein expression of HDAC and HP1 after 24h of cisplatin 
treatment 
Our preliminary data using the V250 proteomics array indicated a possible role for 
HDAC proteins in ovarian cancer in terms of response to chemotherapy. These data 
suggested that HDAC1, HDAC2, HDAC3, and HDAC4 are associated with 
chemotherapy resistance and poor prognosis in cancers (de Ruijter, van Gennip et al. 
2003; Witt, Deubzer et al. 2009; Hayashi, Horiuchi et al. 2010; Stronach, Alfraidi et 
al. 2011). To further investigate in detail whether other HDAC members are involved 
in DNA damage-based treatment, we detected protein expression levels of HDAC 
Class I members (HDAC1, 2, 3, and 8) and IIA (HDAC4) in PEO1 and PEO4 cells 
after cisplatin treatment. As performed in a number of similar studies (Kao, 
McKenna et al. 2003; Yeung, Hoberg et al. 2004; Chinnaiyan, Varambally et al. 
2006; Solomon, Pasupuleti et al. 2006), tubulin was applied as a protein loading 
control in this study. 
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From the nuclear texture results, we observed a change in nuclear texture after 24h of 
cisplatin treatment, thus we supposed that chromatin structure regulators such as 
HDACs would demonstrate changes at this time point. After incubating with 
cisplatin for 24 hours, total protein was collected from PEO1 and PEO4 cells and 
specific protein expression levels detected using antibodies against HDAC1, HDAC2, 
HDAC3, HDAC4, HDAC8, HP1α, HP1β, and HP1γ.  
Among these HDAC family members, the expression level of HDAC2 was enhanced 
approximately 1.5 times compared to the control group after 24 hours cisplatin 
exposure in PEO1 cells, while other protein expression were similar after cisplatin 
treatment (Figure 3.2-5). In PEO4 cells, all of these targets showed little change in 
protein level after cisplatin treatment. This suggests that the class IA member 
HDAC2 might work as a response marker to cisplatin treatment in vitro, and also 
indicates its possible role in chromatin remodelling in DNA damage treatment in 
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Figure 3.2-5 Expression of HDAC family members after cisplatin incubation. Western blot for 
expression of HDAC1, HDAC2, HDAC3, HDAC4, and HDAC8 in PEO1 and PEO4 cells 
with/without cisplatin treatment (6µM, 24h). Membranes were probed with the indicated 
antibodies, and tubulin was used as a loading control. Densitometry measurement is shown in 
Figure S3. 
 
In parallel, by detecting the expression of the HP1 heterochromatin markers, which 
are essential participants during the formation of condensed heterochromatin, we 
also compared the chromatin patterns or the conformation of chromatin in these cell 
lines during cisplatin treatment (Figure3.2-6). Protein expression level of two HP1 
isoforms (HP1α and HP1β) increased by about 30% and 70%, respectively, but only 
in PEO1 cells after 24h treatment of cisplatin, HP1γ protein remained unchanged. 
Compared with PEO1 cells, these heterochromatin proteins in PEO4 cells changed 
little as assessed by the results of western blotting.  










Figure 3.2-6 Expression of heterochromatin proteins after cisplatin incubation. Western blot for 
expression of HP1α, HP1β, and HP1γ in PEO1 and PEO4 cells with/without cisplatin treatment 
(6uM, 24h). Membranes were probed with the indicated antibodies, and tubulin was used as a 
loading control. Densitometry measurement is shown in Figure S3. 
 
The measurement of HP1 protein is another evaluation of chromatin patterns at the 
molecular level, and the consistent expression pattern observed between HDACs and 
HP1s also indicate the involvement of HDAC family members in chromatin 
reorganization during cisplatin or DNA damage-based treatment in cancer.         
 
3.2.3.2 mRNA Expression of HDAC and HP1 after 24h of cisplatin 
treatment 
Since the protein expression of HDAC2 and HP1s showed pronounced change after 
cisplatin treatment in PEO1 cells, we next measured their mRNA expression levels 
to see if this DNA damage-based treatment could also induce similar changes in 
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hours, and mRNA for each target was detected by a two-step real time PCR. As 
illustrated in Figure 3.2-7, mRNA levels of HDAC2, HP1α, HP1β, and HP1γ were 
all significantly elevated by cisplatin treatment (p<0.05) after 24h incubation in 
PEO1 cells (Figure 3.2-7A); however, the mRNA levels remained unchanged in 
PEO4 cells after the same treatment (Figure 3.2-7B). The elevated mRNA level of 
HDAC2 could explain the increase in HDAC2 protein expression after cisplatin 
treatment in PEO1 cells, and also the similar change in HP1 expression suggests that 
heterochromatin increases after treatment.               
 
 






Figure 3.2-7 Expression of HDAC2, HP1α, HP1β, and HP1γ mRNA in PEO1 (A) and PEO4 (B) 
cells by two-step real time PCR. Total RNA was extracted from cells. The cDNA was 
synthesised by reverse transcription, and real time PCR was performed as described in the 
Materials and Methods. Relative expressions of the target gene was calculated as the average 
ΔCt and normalized to that of the housekeeping gene β-actin. The corresponding genes to 
HP1α, HP1β, and HP1γ are CBX5, CBX1, and CBX3, respectively. Results are as presented as 
mean ±SD from biological triplicates. *p<0.05, **p<0.01 (student’s t-test). 
 
This mRNA result is consistent with the changes observed for protein expression 
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not protein. There may be several explanations for this: firstly, it is possible that only 
HP1α and HP1β are effected by cisplatin treatment, since HP1γ has been found not 
only in heterochromatin but also in euchromatin (Dinant and Luijsterburg 2009), 
except for its essential role of being a component of constitutive heterochromatin; 
secondly, the increased expression of HP1γ mRNA at 24h treatment might also 
induce more protein product at a later time point which was not included in the study 
here. 
  
3.2.3.3 Cellular localisation and expression of HDAC2 and HP1s with 
cisplatin treatment 
In order to visualize and confirm these alterations in expression, 
immunofluorescence (IF) was performed on PEO1 and PEO4 cells with or without 
cisplatin treatment by probing with antibodies against HDAC2, HP1α, HP1β, and 
HP1γ with DAPI to highlight the nucleus. Images were taken after 6 hours and 24 
hours by confocal microscopy to establish whether there were any time-dependent 
expression changes in the expression of these proteins (Figure 3.2-8).  
As expected, expression of HDAC2 increased at 24 hours after cisplatin incubation, 
and HP1 proteins showed gradual increases over 0h, 6h, and 24h after cisplatin 
treatment in PEO1 cells (Figure 3.2-8A). In contrast, neither HDAC2 nor HP1 
proteins showed differences in expression during treatment up to 24h in PEO4 cells 
(Figure 3.2-8B). Additionally, the immunofluorescence images showed that all the 
target proteins were stained within nuclei where DAPI was present, which not only 
suggested that the antibody staining was specific, but also demonstrated that the 
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increased expression of these proteins was nuclear and therefore more likely to be 
associated with chromatin structure reorganization.    
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This result strongly supports the findings above, and is direct evidence that  HDAC2 
and heterochromatin accumulate after cisplatin treatment, which is consistent with 
results from western blotting and PCR. In summary, we demonstrate the increased 
expression of HDAC2, HP1α, and HP1β at both protein and mRNA level, and HP1γ 
at mRNA level, supporting the hypothesis that HDAC2 and chromatin reorganization 
are involved with the cellular response to cisplatin treatment, and provide important 
clues to associate HDACs with chromatin remodelling in chemotherapy in cancer. 
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3.3 Role of HDAC2 in DNA damage responses during 
chemotherapy 
From the above results, HDAC2 turned out to be the most significantly changed 
HDAC member in response to cisplatin treatment in vitro, especially in the sensitive 
cell line PEO1, and may have a possible role in chromatin remodelling. Therefore, I 
next explored the detailed role of HDAC2 in the cellular DNA damage response 
(DDR) to DNA damage-based therapy, such as cisplatin treatment, by using a range 
of assays in PEO1 cells, and also expanded some work on PEO4 cells. 
3.3.1 Time-dependent HDAC expression and the cellular DNA damage 
response induced by chemotherapy in ovarian cancer 
Cisplatin has been widely studied for its effect on cellular DNA damage response as 
discussed in the Introduction.  The results above also suggest that HDAC2 is a 
possible response marker after cisplatin treatment in PEO1 cells I therefore next 
asked whether there was any association between HDAC2 and the cellular DNA 
damage response events induced by cisplatin. As one of the most widely used 
chemotherapeutics in a variety of cancers, cisplatin mainly works by forming 
intrastrand and interstrand crosslinks in DNA (Fuertes, Alonso et al. 2003). The 
intrastrand crosslinks are primarily removed via nucleotide excision repair (Kartalou 
and Essigmann 2001). DSB repair pathways, such as HR, also contribute to the 
removal of interstrand crosslinks, which are considered to be crucial cytoxic damage 
to cells (McHugh, Spanswick et al. 2001; Kothandapani, Dangeti et al. 2011). There 
is also evidence showing the possible involvement of HDAC1 and HDAC2 in NHEJ 
(Miller, Tjeertes et al. 2010), but the knowledge about its roles in HR are not fully 
elucidated. The formation of nuclear DSBs triggers phosphorylation of H2AX at 
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Ser139; phosphorylated H2AX is named gamma H2AX (γH2AX). It is believed that 
histone H2AX phosphorylation is required to concentrate essential DNA repair 
proteins at the site of damaged chromatin (Podhorecka 2009). DNA double-strand 
break repair by HR (Schmidt and Schreiber) was shown to be mediated by BRCA1 
phosphorylation at Ser1524, and BRCA1 is required to maintain genome integrity 
(Zhang, Willers et al. 2004). ATM, ATR, and their phosphorylated versions are also 
involved in this DNA damage response pathway. To examine how HDACs associate 
with DNA damage responses induced by cisplatin, we initially evaluated the 
expression of HDAC2 and other HDAC family members in PEO1 cells for a longer 
period of cisplatin treatment (0-96h), together with several DDR pathway players 
(γH2AX, pBRCA1, ATM, pATM, ATR, and pATR) by western blotting.   
Among those HDAC family members, HDAC2 was up-regulated after cisplatin 
treatment at 24h as is stated previously, while expression of other members remained 
at a similar level between treated and untreated groups at early time point (0-48h).  
Meanwhile, expression of HDAC2, HDAC3, and HDAC4 all showed a time-
dependent reduction after cisplatin treatment at the late time points (72h and 96h, 
Figure 3.3-1), and expression of other proteins remained at a similar level throughout 




Figure 3.3-1 Time dependent expression of HDAC-family members and DNA damage response 
proteins in PEO1 cells. Cells were seeded and treated with or without cisplatin (6µM), and 
protein lysates were collected every 24h after treatment from 0h to 96h. Western blotting was 
performed to detect expression of HDAC1, HDAC2, HDAC3, HDAC4, HDAC8, pBRCA1, γH2AX, 
pATM, ATM, pATR, and ATR. Membranes were probed with the indicated antibodies, and 
tubulin was used as a loading control. Experiments were performed at least three times 
acquiring similar results. Blots from one representative experiment are shown.   
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cisplatin, and showed up-regulation of expression after treatment. Expression levels 
of pBRCA1 were increased after 24h of cisplatin treatment in PEO1 cells, and this 
enhancement remained until 96h after therapy. Notably, the level of treated group 
dropped at 96h compared with the treated group at 24h, 48h, and 72h. On the other 
hand, expression of γH2AX, pATM, and pATR also increased after cisplatin 
treatment, and this occurred at late time points from 48h after treatment. Finally, total 
ATM and ATR protein levels remained stable except for a reduction of ATM at the 
late time point of 96h.      
 The results above showed time-dependent expression of pBRCA1, γH2AX, pATM, 
and pATR in PEO1 cells after cisplatin treatment, and the expression patterns varied 
from one protein to another. Meanwhile, expression of HDAC2, HDAC3, HDAC4, 
and HDAC8 also showed a relative time-dependent expression after cisplatin 
treatment, with only increased expression of HDAC2 at 24h. As a marker of double 
strand breaks, elevated γH2AX expression indicated the existence of a DNA damage 
response through the DSB repair pathway during cisplatin treatment in PEO1 cells; 
there is evidence to show that the tumour suppressor function of BRCA1 occurs 
through heterochromatin silencing with increased levels of both heterochromatin and 
BRCA1 after DNA damage treatment (Zhu, Pao et al.). Our results are consistent 
with these findings, and suggest that chromatin remodelling by HDACs might be 
involved in the cellular response to DNA damage therapy, such as double strand 
break and DNA repair. We speculate that HDAC members might act together with 
those pathway players in cellular DNA damage response via heterochromatin 
silencing.  
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3.3.2 Cellular effect of HDAC2 knockdown by siRNA transfection 
The above results implicate HDAC-family members, especially HDAC2, in the 
response to chemotherapy, and demonstrate a possible link between nuclear 
structural changes and cellular DNA damage response. In order to further investigate 
more detailed functions of HDAC2 during cellular DDR, I explored a variety of 
cellular effects by knocking down HDAC2 using siRNA transfection. 
3.3.2.1  Validation of HDAC2 knockdown efficiency 
Gene silencing by RNA interference (RNAi) is nowadays widely used to knock 
down gene expression in order to investigate protein function in a variety of cell 
types. RNAi can be used as a process to moderate the activity of specific genes, and 
there are primarily two types of essential RNAi: micro RNA (miRNA) and small 
interfering RNA (siRNA). siRNA is a group of double-stranded RNA (dsRNA) 
molecules with 20-25 base pairs that works mainly through interfering with the 
expression of specific genes with complementary nucleotide sequences. The stealth 
RNAi we delivered into cells in this study is a 25bp long dsRNA with modification 
on the sense strand, using synthetic methods to ensure that only the anti-sense strand 
is functional to target genes to exclude any off-target effect from the sense strand. It 
is essential to ensure effective knockdown of a targeted gene, thus we evaluated the 
efficiency of our transfection through several approaches together with proper 
controls: 1. non-transfected control was included to judge the baseline level of cell 
viability, phenotype, and target gene level. 2. a negative control not homologous to 
anything in the vertebrate transcriptome was added to determine any sequence-
independent silencing following siRNA delivery in cells. 3. a mock-treated control 
with all the transfection reagents in the absence of siRNA indicated any possible 
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cytotoxicity or other non-specific effects from the transfection procedure. 
Furthermore, time course experiments are also required to find the point of optimal 
knockdown and to ensure the occurrence of acceptable knockdown throughout the 
duration of the experiment. 
3.3.2.1.1 Evaluation of HDAC2 knockdown at the RNA level 
Since the gene silencing from siRNA functions at the mRNA level, I initially 
measured the expression of HDAC2 mRNA directly after transfection using two step 
real-time PCR. PEO1 cells were transfected with high or low concentrations of 
siRNA targeting HDAC2, and the total mRNA was collected from each sample after 
48h, 72h, 96, and 120h of transfection. As is illustrated in Figure 3.3-2, about 40% of 
HDAC2 was knocked down after low concentrations of siRNA (10pmol in 6mL) 
were delivered into PEO1 cells for 48h (p>0.05), and the remaining expression of 
HDAC2 continued decreasing to 15-10% after 72-120h transfection compared with 
the control groups (p<0.05). When a high concentration of siRNA (100pmol in 6mL) 
was transfected, HDAC2 expression was supressed to 11% at the early time point of 
48h (p<=0.001), and remained to 13-15% of control groups throughout the period of 
transfection (p<0.05). Comparison between the control groups indicated that mRNA 
expression levels of HDAC2 changed little, which suggested that the transfection 
method we used here was reliable without detectable sequence-independent silencing 
or non-specific effects on target genes from transfection reagents. Furthermore, the 
pronouncing reduction in HDAC expression indicated that transfection occurred at 
high efficiency. 
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Figure 3.3-2 Expression of HDAC2 in PEO1 cells by two step real-time PCR. Cells were reverse 
transfected (as described previously in the methods) with siRNA (10pmol or 100pmol in 6mL) 
targeting HDAC2, and untransfected group, mock group, and negative control were included as 
controls. Total RNA was extracted from cells at 48h, 72h, 96h, and 120h after transfection. The 
cDNA was synthesised by reverse transcription, and real time PCR was performed as described 
in the Materials and Methods. Relative expression of HDAC2 was calculated as the average ΔCt 
and normalized to that of the housekeeping gene β-actin. Results are as presented as mean 
±SD from triplicate samples. One-way ANOVA followed by Tukey HSD post hoc test was 
performed between groups for statistical analysis (Table S3 for full analysis data). 
 
3.3.2.1.2 Evaluation of HDAC2 knockdown at protein level 
Since the protein is more essential in terms of function during cellular events, it was 
also important to assess the expression of HDAC2 at the protein level after siRNA 
transfection. As a well-optimised method in this study, we primarily observed 
protein expression of HDAC2 in PEO1 cells by using the HDAC2 antibody in an 
immunofluorescence assay. Corresponding to the method we applied above, the three 
controls were also included to evaluate transfection efficiency, and the IF result is 














































ere seeded on cover glasses and 






 and high concentration) for 72h, and untransfected, m
ock, and negative control 
w
ere used as control groups. A
lexa488 (green channel) and D
A
PI (blue channel) w
ere used to stain target proteins and nuclei, respectively. Pictures w
ere 






























10pmol 100pmol 10pmol 100pmol 
The protein expression of HDAC2 was considerably reduced, as shown in the green 
channel with either low or high concentrations of delivered siRNA duplex, compared 
to control groups. Similar to the RNA expression result, protein levels of HDAC2 
varied little among the three controls; meanwhile, the knockdown of HDAC2 
expression was highly effective with a very low application of transfection reagents. 
We also detected the expression of HP1α in PEO1 cells with HDAC2 knockdown. 
As was expected, there was minor fluorescence detected (green channel in Figure 
3.3-3B) in the transfected group, which indicated that the amount of HP1α protein in 
the nucleus was abundantly reduced in cells after siRNA transfection. These 
chromatin pattern changes as measured by HP1 protein expression directly supports 
the role of HDAC2 in chromatin organization. 
To achieve more accurate and specific measurement of HDAC2 expression, western 
blotting was performed to investigate the target protein level after gene knockdown. 
The same time course experiment to that used for RNA detection above was carried 
out to detect protein expression from 48h to 120h after gene knockdown (Figure 3.3-
4). The decreased expression of HDAC2 occurred as early as 48h with about 70% 
reduction in protein expression under both concentrations of siRNA duplex, and the 
knockdown effect also remained at around 70% suppression of protein expression 
from 72-120h. 
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These measurements established that the RNAi method we applied here successfully 
silenced HDAC2 with high efficiency at both mRNA and protein level even at lower 
concentrations of RNAi, and the undetected sequence-independent silencing and 
non-specific effect from transfection reagents provided acceptable confidence in this 
RNAi as a reliable method for future studies on the functions of HDAC2. 
 
3.3.2.2 Effect of HDAC2 knockdown on cell morphology and growth in 
PEO1 cells 
The morphology of PEO1 cells was observed after 72 hours incubation with siRNA 
transfection under the light microscope, and comparisons were made between the 
knocked-down samples and the controls (non-transfection, mock, and negative 
siRNA control). Figure 3.3-5 shows representative pictures from the study of the 
cellular morphology of PEO1 cells after HDAC2 expression was knocked down. 
Cells settled in the dishes as a monolayer with either normal medium or transfection 
reagents. After 72h treatment, the shape and appearance of those cell adherent to 
dishes remained similar, while noticeably there was a large number of round-shaped 
cells floating in the medium with the siHDAC2 duplex, leaving less cells attached to 
the dishes. This result indicated that HDAC2 might have an effect on cell growth or 
viability and colony formation in PEO1 cells, and the reduction of attached cell 
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3.3.2.3 Expression profiling of other HDAC family members, 
heterochromatin proteins, and DNA damage response proteins 
under HDAC2 suppression  
After the RNAi methodology was validated, I next examined the effect of HDAC2 
depletion on the expression of other HDAC family members, and target proteins by 
western blotting (Figure 3.3-5, panel 1-5).  Apart from the effective depletion of 
HDAC2 expression even at the lower concentration of siRNA (10pmol), protein 
levels of HDAC3, HDAC4, and HDAC8 were not significantly affected by 
knockdown of HDAC2, which showed a fairly specific suppression of HDAC2 using 
RNAi without off-target effect on these HDAC members. Interestingly, HDAC1 
expression was mildly up-regulated after HDAC2 knockdown, which indicated a 
possible compensatory effect between HDAC1 and HDAC2 in PEO1 cells. This 
compensatory mechanism between HDAC1 and HDAC2 has previously been 
reported in several studies (Wilting, Yanover et al. 2010; Yamaguchi, Cubizolles et 
al. 2010; Jurkin, Zupkovitz et al. 2011). 
Since HDAC2 was implicated in heterochromatin formation as indicated by HP1 
expression measured by IF above, we further assessed the expression of all three 
heterochromatin protein isoforms after siRNA transfection (Figure 3.3-5, panel 6-8) 
by western blotting. HP1 proteins exhibited a little alteration, with mild down-
regulation (20%) of HP1α expression after siHDAC2 was transfected. The down-
regulation of HP1α from both IF and western blotting suggests HDAC2 participates 
in the nuclear chromatin organisation to some degree; nevertheless we would 
speculate that considerable alteration of chromatin organization might result from the 
 133 
cooperative effect from several HDAC family members, in terms of the relatively 
stable observed expression of HP1β and HP1γ. 
To decipher whether those DDR proteins mentioned previously were affected in 
HDAC2 knockdown cells, we examined their expression. After 72h depletion of 
HDAC2, there was a dramatically significant up-regulation of γH2AX and reduction 
of pBRCA1 (Figure 3.3-6, panel 9-10). In contrast, the stability of other DDR 
proteins (pATM, ATM, pATR, ATR, and Rad51 in Figure3.3-6, panel 11-15) was 
not obviously affected. This result implies accumulation of double strand breaks and 
possible reduced DNA repair induced by suppression of HDAC2 expression, 
although the up-regulation of γH2AX might also indicate that the cells are 


















Figure 3.3-6 The effect of siHDAC2 on expression of other HDAC family members (panel 1-5), 
HP1s (panel 6-8), and DNA damage response proteins (panel 9-15) by western blot in PEO1 cells. 
Protein was lysed after HDAC2 was knocked down after 72h using reverse transfection. Non-
transfection (control), mock, and siRNA negative control. were used as controls. Membranes 
were probed with the indicated antibodies, and tubulin was used as a loading control (panel 16). 
Experiments were performed at least three time acquiring similar results. Blots from one 


















      







     
   
   











   
   
     
   
   
   

























3.3.2.4 Characterisation of cellular responses to cisplatin treatment in 
ovarian cancer cells when HDAC2 is potently inhibited 
Since these data implied an association between HDAC2 and the DNA damage 
response to cisplatin, I next explored the roles by which HDAC2 contributed to the 
DNA damage response induced by cisplatin. Here I broadened the detection of DDR 
proteins with HDAC2 siRNA transfection and cisplatin treatment in both PEO1 and 
PEO4 cells. After cells were transfected with HDAC2 siRNA for 72 hours (low 
concentration of 10pmol/6mL applied for acceptable transfection efficiency), I 
treated them with cisplatin and collected cellular protein after 6-96h of incubation 
with cisplatin.  
Western blotting results from PEO1 cells are shown in Figure 3.3-7. Consistently, 
HDAC2 showed early up-regulation at 24h and late down-regulation during cisplatin 
treatment in those control groups without HDAC2 knockdown. Not surprisingly, the 
induction of DSBs indicated by γH2AX occurred as early as 6h, while interestingly 
we discovered an accumulation of γH2AX expression after 24 hours of cisplatin 
treatment in cells with HDAC2 depletion, compared with either the cisplatin treated 
group or HDAC2 knockdown-only groups. This accumulation effect from both 
siHDAC and cisplatin seemed to be gradually lost during the incubation time until 
72h. In Figure 3.3-1, the up-regulation of several DNA damage response proteins 
was noted during cisplatin treatment; I therefore examined their expression in 
response to cisplatin treatment after HDAC2 was depleted, and also included another 
major player in DSBs repair, particularly in homologous recombination (Baumann 
and West 1998). As expected, pBRCA1, pATM, pATR, and Rad51 participated in 
DDR triggered by cisplatin at certain time points (6h, 24h, 48h, and 24h respectively) 
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with increased expression compared with untreated controls. By contrast, cisplatin 
caused dramatically reduced expression of those proteins in cells with HDAC2 
knockdown, which was demonstrated apparently in the last lane at various time 
points from 24h to 72h in Figure 3.3-7.  
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To clarify further the involvement of HDAC2 during cellular DDR by cisplatin, the 
same assessment was performed in the cisplatin-resistant PEO4 cell line (Figure 3.3-
8). HDAC2 in PEO4 cell exhibited little alteration during cisplatin treatment except 
for decreased expression at relatively late time point of 72h; however, the siRNA 
also successfully silenced the expression of HDAC2 in PEO4 cells. Differing from 
PEO1 cells, cumulative effect from both HDAC2 depletion and cisplatin on γH2AX 
was not observed in PEO4 cells, although there was induction of DSBs from 24h by 
cisplatin when we compared the cisplatin-treated groups with those without drug 
incubation. Additionally, expression of pBRCA1, pATM, and RAD51 were elevated 
by cisplatin treatment only, indicating the activated DNA damage response pathway 
via these proteins. Similarly, suppression of this activation by HDAC2 depletion was 
displayed through decreased levels of pBRCA1, ATM, pATR, and RAD51, though 
the pattern of DDR interruption from siHDAC2 was distinct between PEO1 and 
PEO4 cells, which was different over time.          
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To summarise the results from the PEO1 and PEO4 cell lines, I demonstrated the 
participation of multiple DDR proteins (γH2AX, pBRCA1, pATM, ATM, pATR, 
ATR, and RAD51) and induction of DSBs by cisplatin in both PEO1 and PEO4 cells. 
Moreover, suppression of DDR activation occurred after HDAC2 knockdown by 
RNAi, which strongly suggested the involvement of HDAC2 in the cellular response 
to the DNA damage-based treatment. The differences between PEO1 and PEO4 cells 
in the manner of DSB accumulation and time point of pathway activation or 
suppression might be due to the nature of the two cell lines in terms of their cisplatin 
sensitivity. The two major pathways for DSB repair, NHEJ and HR, have 
compensatory effects to each other (Jeggo, Geuting et al. 2011). The balance 
between them might be disrupted by the distinct status of BRCA2 in PEO1 and 
PEO4 cells, which might influence the dominant repair mechanism in the two cell 
lines and cause the functional activity of those DNA damage response proteins at 
different stages after cisplatin treatment. Furthermore, HDAC2 also showed a 
different pattern of involvement during DDR induced by cisplatin between sensitive 
and resistant cells. 
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3.3.2.5 Role of HDAC2 in γH2AX foci formation during cisplatin 
treatment 
As a marker for DSB, one of the histone variants of H2AX is phosphorylated at 
ser139 after being exposed to DNA damage factors, namely γH2AX (Rogakou, Pilch 
et al. 1998). It has been demonstrated that γH2AX could locally form foci at the 
DNA damaged domains, and has been suggested to be a profoundly sensitive marker 
of interstrand crosslinking DNA damage induced by cisplatin (Clingen, Wu et al. 
2008). Additionally, γH2AX foci play an essential role in the process of recruitment 
of a range of DNA damage response factors, such as the checkpoint protein 53BP1 
(Ward, Minn et al. 2003), and is vitally responsible for the cellular DNA damage 
response with co-localization with various DDR components including ATM, 
BRCA1, and RAD51. (Fernandez-Capetillo, Celeste et al. 2003). The detection of 
immunofluorescently-stained γH2AX foci has been widely applied to evaluate the 
degree of DSB damage. From the above results, HDAC2 has been shown to be 
important during cellular DDR, which prompted me to further define its role in DSBs 
in terms of γH2AX foci formation in cells with HDAC2 depletion. PEO1 and PEO4 
cells were grown on coverslips as usual, and nuclei and γH2AX were stained as 
described before. The γH2AX foci were recognized and visualised using 
immunofluorescence microscopy. 
After treating cell with cisplatin for 24h, I noticed γH2AX foci formation in both 
PEO1 (Figrure3.3-9A) and PE04 (Figure3.3-9B) cells without siRNA (NC+cisplatin 
group). This is not surprising and consistent with the previous observation showing 
the remarkable accumulation of γH2AX foci after cisplatin treatment in cells (Huang, 
Okafuji et al. 2004). Within cells transfected with HDAC2 siRNA, there was also 
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production of γH2AX foci in both cell lines (siRNA group in Figure 3.3-9 A and B), 
and immunofluorescent signal from γH2AX antibody exhibited similar intensity to 
that in cisplatin treated groups. It is also noteworthy to point out that the γH2AX 
staining in PEO4 cells with HDAC2 knockdown displayed more heterogeneity with 
high intensity for the foci in a few cells and near background staining in other cells. 
Furthermore, by investigating the foci formation in cells treated with cisplatin after 
HDAC2 knockdown, a remarkable increased production of γH2AX foci was 
recognized in PEO1 cells (siRNA+cisplatin group in Figure3.3-9A) with both 
enhanced number and intensity of foci compared with other groups. In PEO4 cells, 
this accumulative effect from both siRNA and cisplatin was not as obvious as PEO1 
cells, with a similar signal to that in cells treated with cisplatin alone 















Figure 3.3-9 Immunofluorescent staining for γH2AX foci in PEO1 (A) and PEO4 (B) cells. Cells 
were grown and treated as described before, and images were taken after 24-hour treatment of 
cisplatin in cells with or without HDAC2 siRNA. Antibodies against H2AX phosphorylation at 
Ser 139 were used to probe cellular γH2AX foci (red channel), and DAPI was applied for nuclear 
staining (blue channel). Representative images from one experiment were shown. More that 100 
cells in each group were included for one experiment, and three independent experiments were 









γH2AX DAPI merge 
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To quantitatively analyse γH2AX foci in my experiments, I counted the number of 
foci in each cell using the PZ Foci EZ plugin in ImageJ software as described in 
Materials and Methods, and more than 100 nuclei were included in each single 
experiment. Less than 5 clustered γH2AX foci were detected in the majority of the 
cell population in the control groups in PEO1 (Figure 3.3-10A) and POE4 (Figure 
3.3-10B) cells from the distribution figures, indicating the background level. The 
main population distribution switched to the side with more foci per cell after either 
cisplatin or siRNA plus cisplatin treatment (6-15 and 16-30 foci per cell, Figure 3.3-
10A) in PEO1 cells. In contrast, only cisplatin treatment caused an obvious alteration 
of foci number distribution in PEO4 cells with 16-30 foci per cell in most of the cells 
within the group, and the combined treatment with siRNA and cisplatin might affect 
the cell distribution with excess numbers of cells with large numbers of foci (>=16) 






Figure 3.3-10 Distribution of γH2AX foci per cell at 24h after cisplatin treatment with or without 
HDAC2 knockdown in PEO1 (A) and PEO4 (B) cells. The percentage of targeted cells with 
different γH2AX foci numbers (0, 1-5, 6-15, 16-30, >30) is given. One representative experiment 






















































As a result, we set the 5 foci per cell as threshold for background level, and cells 
with 5 or less foci were defined as negative and more than 5 as positive. To acquire a 
statistical analysis for γH2AX foci formation, the percentage of cells with positive 
staining was calculated in each group, and the number was compared with negative 
controls in each cell line (Figure 3.3-11). In parallel with observations from IF 
staining, the number of PEO1 cells with positive foci significantly increased after 
either cisplatin treatment or HDAC2 knockdown, and additional foci were induced 
by cisplatin treatment in cells with HDAC2 depletion (p<0.05 and 0.01 compared 
with cisplatin-treated and siRNA transfected groups, respectively, Figure 3.3-11). 
The most significant effect on foci formation in PEO4 cells was generated by 
cisplatin treatment (p<0.001), while HDAC2 knockdown alone changed little the cell 
percentage with positive foci number compared with background levels. Among the 
groups, knockdown of HDAC2 also significantly increased the cell number with 
positive γH2AX foci (p=0.032), although this depletion showed minor restoration for 






Figure 3.3-11 Relative cell number percentage with positive γH2AX foci (more that 5 foci per 
cell) calculated compared to background levels (negative control group, NC).  Each column 
represents the average data from 3 independent experiments, and error bars represent the SD 
of average foci per cell. One-way ANOVA followed by the HSD post hoc test was performed 







































































This result is consistent with our previous data from western blotting showing the 
cumulative effect of HDAC2 knockdown on protein expression of γH2AX after 
cisplatin treatment, which was not observed in PEO4 cells but opposite with minor 
reductions in γH2AX level (Figure 3.3-7 and Figure 3.3-8). The enhanced number of 
γH2AX foci caused by HDAC2 knockdown during cisplatin treatment in PEO1 cells 
indicated either compromised repair during DNA damage or persistent production by 
cisplatin (Burdak-Rothkamm, Short et al. 2007), and this could be further examined 
by prolonged incubation in drug-free medium to monitor repair ability. The data here 
supported our hypothesis, and therefore emphasized the important roles of HDAC2 
in cellular DDR, especially during DSB indicated by H2AX foci induced by cisplatin, 
by participating in the DDR pathways, but also suggested a possible different manner 
between sensitive and resistant cells in DDR. 
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3.3.2.6 Cell fate determination by HDAC2 knockdown during cisplatin 
treatment 
As shown in section 3.2, the pan-HDAC inhibitor for class I and II mammalian 
HDACs, TSA, showed suppressive effects on cell number in both PEO1 and PEO4 
cells, and also further inhibited cell number when combined with cisplatin treatment. 
Since HDAC2 appeared to be involved in cisplatin-induced cellular DNA damage 
response events, we further explored the effect of specific HDAC2 knockdown on 
cell fate by measuring cell growth number, cell cycle distribution, and apoptosis.   
3.3.2.6.1 Cell morphology study after cisplatin treatment in PEO1 and PEO4 
cells with HDAC2 knockdown 
Firstly, the morphology of the cell lines with HDAC2 depletion was observed after 5 
days treatment with cisplatin. As is shown in Figure 3.3-12, PEO1 (A) and PEO4 (B) 
cells were settled as a monolayer, and the cell number obviously decreased in the 
HDAC2 knockdown only group compared with control groups, which has been 
already indicated when we studied the effect of HDAC2 depletion on cell 
morphology in PEO1 cells (Figure 3.3-5). Here we also observed a similar 
phenomenon in PEO4 cells, and cell number was even significantly reduced with 
cisplatin treatment in HDAC2 knockdown groups compared with siHDAC2, 
cisplatin treated, or control groups in both cell lines. The floating cells also indicated 
possible cell death induced by cisplatin and HDAC2 knockdown. The cell growth 
inhibited by HDAC2 in both cisplatin sensitive and resistant cells suggested the 
possible role of HDAC2 to affect the cell’s susceptibility to DNA damage-based 












Figure 3.3-12 The effect of HDAC2 knockdown on cellular morphology of PEO1 (A) and PEO4 
(B) cells after cisplatin treatment. PEO1 (A) and PEO4 (B) cells were grown on dishes and 
reverse transfected with HDAC2 siRNA for 72h, followed by treatment with cisplatin (6µM) for 5 
days. Images were taken by light microscope, and mock and negative control siRNA were 
applied as controls. 





3.3.2.6.2 Effect of HDAC2 knockdown on cell growth during cisplatin 
treatment  
To quantitatively assess the inhibitory effect of HDAC2 knockdown during cisplatin 
treatment on cell growth, the SRB assay was utilized to measure the cell number in 
each group. After being transfected with HDAC2 siRNA, cells were treated with 7 
concentrations of cisplatin by a titration from 0.1µM to 15µM. The SRB assay was 
performed on day 5 to detect the remaining cell number after treatment.  
The concentration-survival curve in Figure 3.3-13 shows that cisplatin treatment 
(blue line) caused cell growth inhibition in a dose-dependent manner in both the 
control group and the HDAC2 knockdown group in both PEO1 (Figure 3.3-13A) and 
PEO4 (Figure3.3-13B) cells. Here the curves with or without HDAC2 depletion 
show similar pattern in both cell lines, which implies that the inhibitory effect from 







Figure 3.3-13 sulforhodamine B assay profile for inhibitory 50% concentration (IC50) of cisplatin 
on PEO1 (A) and PEO4 (B) cells with (green line) and without (blue line) HDAC2 knockdown.  
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siRNA- 2.29 3.31 
siRNA+ 0.75 0.53 
Inhibitory ratio (%) 67.4 83.9 
 
Table 3-5 Summary data for cisplatin inhibitory ratio of PEO1 and PEO4. Data are from the SRB 
assay above, and sensitization ratios were calculated by comparing IC50 in cells with siRNA to 
that without siRNA.  
 
The concentration that caused an inhibition of cell growth in 50% of the treated cells 
(IC50) was calculated for each group as listed in Table 3.3-1. Growth of both cell 
lines was further inhibited by cisplatin after HDAC2 knockdown, with extra 67.4%  
inhibitory ratio in PEO1 cells and 83.9% in PEO4 cells, and this data suggests an 
additive effect of growth inhibition between HDAC2 depletion and cisplatin. 
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3.3.2.6.3 Alteration of cell cycle progression during cisplatin treatment with 
HDAC2 knockdown  
The cell cycle alterations triggered by cisplatin have been intensively investigated, 
and several studies have identified cellular S or G2 phase arrest after cisplatin 
treatment (Sorenson, Barry et al. 1990; Lee, Brown et al. 1999). Moreover, a large 
number of proteins in cellular DDR are essential for cell cycle arrest after DNA 
damage-based therapies, such as ATM, ATR, and BRCA1 (Deng 2006; Santra, 
Wajapeyee et al. 2009). Following the inhibitory effects of HDAC2 knockdown on 
cell growth, it raised the question as to the mechanism during this suppression. One 
explanation for this might be that knockdown of HDAC2 was involved in the cell 
cycle progression induced by cisplatin. Therefore I examined the cell cycle 
distribution change in both PEO1 and PEO4 cells with HDAC2 depletion during 
cisplatin treatment. 
Cells were transfected with HDAC2-targeted siRNA, followed by treatment with 
cisplatin. Cell cycle distribution analysis was performed after 72h, and multiple 
control groups were included as before (untransfected, mock, and negative control 
siRNA). Figure 3.3-14 showed the cell cycle distribution for G0/1, S, and G2/M for 
each group in PEO1 (A) and PEO4 (B) cells. Not surprisingly, cisplatin treatment 
induced significant S phase arrest in both PEO1 (+160%, P<0.001) and PEO4 cells 
(+180%, P<0.001) compared to control groups, and decreased cell number in G1 
phase (-30% and -40%, in PEO1 and PEO4 respectively, P<0.05). Knockdown of 
HDAC2 only altered the cell cycle distribution in PEO1 cells by increasing the S 
phase population (+120%, P<0.05). As expected, treatment with cisplatin in cells 
with HDAC2 depletion altered cell cycle distribution in both PEO1 and PEO4 cells 
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compared with cisplatin treated cells without transfection, but in different manners. 
Knockdown of HDAC2 further caused S phase arrest induced by cisplatin in PEO1 
cell (+120%, P<0.05), and additional reduction of G1 phase (-20%, P<0.001). In 
contrast, depletion of HDAC2 seemed to reverse the cell cycle arrest caused by 
cisplatin by reducing S phase accumulation (-20%, P<0.001) and increasing G1 
phase population (+140%, P<0.05) based on the measurement for cisplatin treated 
cells without transfection.      






Figure 3.3-14 The effect of HDAC2 knockdown on cell cycle distribution of PEO1 (A) and PEO4 
(B) cells. Cells were reverse transfected with HDAC2 siRNA, followed by treatment with 
cisplatin for 72 hours. Three controls were included as described before. Cell number 
percentages of the populations selected in G0/1, S, G2/M phases of the cell cycle were detected 
by flow cytometry. Columns represent the mean percentage of triplicate independent samples. 
Error bars represent SD. Brown-Forsythe test followed by Games-Howell pot HOC test were 






















































These cell-cycle parameter alterations strongly suggest involvement of HDAC2 in 
the cellular response to cisplatin in terms of cell cycle distribution. Additionally, the 
cumulative effect in PEO1 cells and restorative effect in PEO4 cells indicated 
HDAC2 might function through different pathways to participate in the cellular 
response to cisplatin treatment, which is parallel with the above findings about the 
distinctive cellular effects of HDAC2 on PEO1 and PEO4 cells and also imply that 
there is a possible association with platinum sensitivity in ovarian cancers. 
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3.3.2.6.4 Cellular apoptosis induction by HDAC2 knockdown during cisplatin 
treatment 
To further detect the cellular effects of HDAC2 knockdown during cisplatin 
treatment, I investigated the apoptotic events in PEO1 and PEO4 cells. Cell were 
grown and treated using the same procedure as above, and apoptotic cell numbers 
with positive annexin V staining were calculated by flow cytometry after 72h 
treatment of cisplatin. Because of its property to bind to the translocated membrane 
phospholipid phosphatidylserine (Hirning, Zuna et al.) during the initial process of 
apoptosis, the annexin V assay can identify apoptosis at earlier stage, and the cells 
undergoing late apoptosis can be detected by both Aneexin V and propidium iodide 
(PI) positivity, which only occurs in dead and membrane damaged cells. 
Firgure 3.3-15 showed the apoptosis analysis in PEO1 (A) and PEO4 (B) cells after 
cisplatin treatment in cells with or without HDAC2 knockdown. Only Cisplatin 
induced early apoptosis in PEO1 cells (P<0.001), but not late apoptosis in PEO1 
cells or PEO4 cells. This  was consistent with the resistance of the PEO4 cell line to 
cisplatin treatment compared with PEO1 cells. Additionally, knockdown of HDAC2 
remarkably caused cellular apoptosis in both early and late stage in PEO1 cells and 
only an early apoptosis event in PEO4 cells, compared with controls and cisplatin 
only groups (P<0.001). Furthermore, HDAC2 depletion induced significant 
accumulation of apoptotic cells after cisplatin treatment in both cell lines, especially 
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Figure 3.3-15 The effect of HDAC2 knockdown on apoptosis in PEO1 (A) and PEO4 (B) cells 
using the Annexin V assay. Cells were reverse transfected with HDAC2 siRNA, followed by 
treatment with cisplatin for 72 hours. Three controls were included as described before. Cell 
number percentages of the population selected with positive Annexin V staining were detected 
by flow cytometry after cisplatin treatment for 72h, and data are separated into early and late 
apoptosis based on Propidium Iodide (PI) signal. Columns represent the mean percentage of 
triplicate independent samples. Error bars represent SD. One-way ANOVA analysis was 
performed to compare data among groups, and the Tukey HSD pot HOC test was used to 






































































By knocking down HDAC2, I observed a greater apoptotic cell population with 
cisplatin treatment in both PEO1 and PEO4 cells, suggesting the cell growth 
inhibition from HDAC2 depletion during cisplatin treatment might be generated by 
apoptosis induction, and the detailed minor differences in PEO1 and PEO4 also 
indicated diverse roles HDAC2 might play in cells in terms of platinum sensitivity. 
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3.4 Reversibility of HDAC inhibition on nuclear morphological 
changes during cisplatin treatment 
The results above demonstrate the involvement of HDAC2 during cellular DDR 
induced by cisplatin, and also demonstrate the nuclear morphological changes during 
DNA damage-based therapies in ovarian cancer cell lines. To test if this nuclear 
structure change was causally mediated by HDAC, or specifically HDAC2, we 
investigated the reversibility of nuclear morphology by applying either HDAC 
inhibitor or HDAC2 siRNA in PEO1 cells. 
We initially examined the nuclear structure in PEO1 cells after treatment with 
HDAC inhibitor TSA. Similar to the method we used before, nuclear texture was 
measured in ImageJ after cells were treated with TSA for 24h. As expected, the five 
texture parameters were altered after TSA treatment: angular second moment, 
correlation, and inverse difference moment were elevated, while entropy and contrast 
were decreased after HDAC inhibition (Figure 3.4-1). By relating those parameters 
with certain chromatin patterns as described previously, we identified decreased 
heterogeneity and contrast of chromatin structure, and increased homogeneity (see 
below summary in Table 3.4-1) after treating cells with TSA. This is consistent with 
the current knowledge about the roles of HDAC in forming tight chromatin structure, 
and suggested that this condensed construction is reversible by using an HDAC 




Figure 3.4-1 Changes of nuclear texture features in PEO1 cells after TSA treatment. PEO1 cells 
were grown on coverslips and treated with TSA (250nM) for 24h, and nuclei were stained with 
DAPI for visualisation using a fluorescence microscope. At least 100 nuclei were included in 
one experiment. Nuclear texture was analysed by measuring five texture parameters (angular 
second moment, correlation, entropy, inverse different moment, and contrast) in ImageJ 
software. Data are presented as the average change (%) in TSA treated group for each 
parameter over control group.  
 
To further explore the reversibility of nuclear morphology, we applied the specific 
HDAC2 siRNA to evaluate the changes of chromatin pattern during cisplatin 
treatment (Figure 3.4-2), since HDAC2 showed potential in the response to cisplatin 
in our study. Cisplatin treatment here consistently altered those parameters, which 
caused similar effects on nuclear texture with the results shown earlier with enhanced 
heterogeneity and reduced homogeneity. When comparing the outcome between the 
HDAC2 knockdown group and cisplatin treated group, we noticed the completely 
opposite direction in the parameter changes caused by the two treatments, indicating 
the ability of specific HDAC2 silencing in altering chromatin patterns (Table 3.4-1). 
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The nuclear texture changes caused by both cisplatin and siHDAC2 resulted in a 
complicated set of changes. Changes of two parameters (angular second moment and 
correlation) induced by cisplatin were reversed by HDAC2 knockdown. On the other 
hand, alterations of the other parameters (entropy, inverse difference moment, and 
contrast) in cells treated with both cisplatin and siHDAC2 were enhanced from the 
levels changed by cisplatin.  













Contrast (+)  
1 TSA 
               
 
2 siHDAC2 
                               
 
3 cisplatin  
 
 
4 siHDAC2+cis                _  
Table 3-6 Summary of nuclear texture analysis. 
 
To summarize the result of nuclear texture analysis, we demonstrated nuclear 
morphological changes induced by DNA damage-based therapies, including cisplatin, 
in terms of homogeneity and heterogeneity. We also identified that suppression of 
HDAC, especially HDAC2, could alter the nuclear structure, indicating the roles of 
HDAC participating in mediating certain chromatin conformations. HDAC2 
silencing reversed the nuclear texture alteration caused by cisplatin to some degree, 
but not completely. There are several considerations for this: firstly, the desired 
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reversibility might occur quite early, since we suppose HDAC2 is an early mediator 
of DNA damage response which occurs only minutes after cellular response (Trainor, 
Butterworth et al. 2012); furthermore, the compensatory effect of HDAC1 from 
HDAC2 depletion might also interfere with the nuclear structure and cause a 
comprehensive consequence; additionally, the balance between HDAC and other 
chromatin structure regulators might be interrupted by HDAC2 knockdown, which 
may lead to possible negative feedback to affect chromatin patterns.  
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3.5 Profiling expression of HDAC and HP1 proteins in the ovarian 
cancer xenograft model 
To investigate in detail the mechanisms mediating response in ovarian cancer, two 
human ovarian cancer xenograft models were established in our lab, OV1002 and 
HOX424. Female adult CD-1 nude mice housed in IVCs (individually ventilated 
cages) were treated with carboplatin (50 mg/kg i.p.) on day 0, and tumour samples 
were collected on day 0, 1, 4, 7, and 14 after treatment. The OV1002 model showed 
much more sensitivity to carboplatin treatment compared to the HOX424 model. 
All xenograft tumour samples were spotted on TMA slides and expression of HDAC 
members (HDAC1, 2, 3, 4, and 8) and HP1 isoforms (HP1α, HP1β, and HP1γ) were 
detected by immunofluorescence as described in the Materials and Methods. The 
results of IF were scored and analysed by automated quantitative analysis (AQUA) 
system. After the image of each TMA slides was acquired, the normalized 
immunofluorescence intensities (AQUA scores) of targets were obtained from 
triplicate cores of each sample. 
Interestingly, HDAC2, HDAC8 and all three HP1 proteins showed statistically 
significantly increased expression in the sensitive model (OV1002) after carboplatin 
treatment, and the most significant changes (p<0.05) were observed on day 7 (Figure 
3.5-1). Expression of these proteins remained similar between control and treated 
groups in the HOX424 model on the same day after treatment.   
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Representative immunofluorescence images for expression of these HDAC and HP1 
proteins in the xenograft model OV1002 are also shown in Figure 3.5-2. The proteins 
were located in the nuclear compartment, and were obviously highly expressed in 
tumours after chemotherapy compared with the expression in control group (red 



































Figure 3.5-2 Representative images for detection of HDAC members and HP1 isoforms in 
ovarian tumour xenografts in the non-treated group and carboplatin-treated group. Sample 
TMAs were probed using the indicated primary antibodies and immunofluorescence images 
were visualised by using AQUAsition software at 20x magnification via DAPI, CY3, and CY5 
channels. Blue = DAPI nuclear counterstain, green = cytokeratin tumour mask and red = target 
protein. 
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This result showed increased expression of HDAC members (HDAC2 and HDAC8) 
in vivo in response to platinum treatment, as well as enhanced heterogeneity of 
chromatin indicated by the expression of HP1s, providing strong evidence to support 
our hypothesis, and suggested that HDACs have a role in mediating chromatin 
remodelling during DNA damage therapy in ovarian cancer. The result here is much 
more significant compared to the observations in vitro above. One explanation might 
be that HDACs and HP1s function in a tissue-dependent manner, with specific roles 
in different tissue or growing environments (human, xenograft, and cell line). 
Another theory would be the differences during 2D and 3D culture, since this has 
been suggested in the literature about the interrelation between cell morphology and 
cellular event based on chromatin organization (Storch, Eke et al.). 
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3.6 Exploring expression of HDAC members, HP1 isoforms, and 
chromatin patterns in human ovarian cancer samples 
The next stage of our study focused on the investigation in clinical tumour samples 
of HDAC expression and chromatin patterns. 38 patients, 76-paired samples were 
included in this final study, and these samples were acquired from patients pre-
treatment and post-treatment during chemotherapy, 20 cases of which showed 
sensitivity to chemotherapy while the other 18 patients were resistant or refractory 
based on the overall disease response categories (RECIST) in response to first-line 
chemotherapy (see Table S8 for full sample information). 
3.6.1 Differential expression of HDAC and HP1 proteins in clinical 
ovarian tumours 
I explored HDAC1, HDAC2, HDAC3, HDAC4, HDAC8, and three HP1 isoform 
expression in the ovarian tumour samples. The results of IF were scored and 
analysed by the automated quantitative analysis (AQUA) system. After the image of 
each TMA slides was acquired, the normalized immunofluorescence intensities 
(AQUA scores) of these targets were obtained from triplicate cores of each sample as 
described in the Materials and Methods.  
After analysing the AQUA scores, only HDAC4 (p=0.026) and HP1γ (P=0.04) 
showed a significant increase in patients after chemotherapy compared to the 
expression level before chemotherapy (Figure 3.6-1A and C), with HDAC8 reaching 
borderline significance (p=0.05, Figure 3.6-1B). By separating patients into sensitive 
and resistant groups, this increased expression seems to be contributed mainly by 
patients sensitive to chemotherapy; here we didn’t observed such differences in 
HDAC1, HDAC2, HDAC3, HP1α or HP1β expression as in the cell line results 
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(Figure S1 in supplement), This might be due to the heterogeneity of cancer tissues, 
differences between cell line model and human samples, or the relatively low sample 











































































































s in ovarian cancer tum
ours from












 and data from
 proteins w







ple for pre- and post-treatm
ent, and P
 values are indicated. First panel show
s the total data from
 38 patients, w
hile 
the last tw
o panel presents com
parison m
ade w




































Here we also showed some immunofluorescence images from different patients with 
significantly enhanced expression of these HDAC and HP1 proteins after 
chemotherapy in Figure 3.6-2. Remarkably increased expression was observed in 
some patients, although the enhancement varied between patients. Similar to the 
results from xenografts, the proteins were located in the nuclear compartment, and 
were obviously highly expressed in tumours after chemotherapy compared with the 
expression in control group (red channel in Figure 3.6-2).  
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A. HDAC4 
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Figure 3.6-2 Selected images for detection of HDAC members and HP1 isoforms in matched 
clinical ovarian tumours pre- and post-chemotherapy. Sample TMAs were probed using the 
indicated primary antibodies and immunofluorescence images were visualised by using 
AQUAsition software at 20x magnification via the DAPI, CY3, and CY5 channels. Blue = DAPI 
nuclear counterstain, green = cytokeration tumour mask and red = target protein. Images from 
those proteins with significant change of expression are shown here. 
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To further investigate the correlation between HP1 and HDAC proteins, Spearman’s 
correlation coefficients were measured for every combination of HDACs and HP1s 
(Table 3.6-1). In this statistical analysis, HDAC1, HDAC2, HDAC8, and all HP1 
proteins showed a correlation with each other (P<0.05). Among these compared pairs, 
HDAC2, HDAC4, HDAC8, and HP1γ showed higher correlation (correlation 
coefficient>0.5, highlighted in Table3.6-1), indicating the association of HDACs and 
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3.6.2 Nuclear texture study in clinical ovarian tumours 
To test our hypothesis in clinical tumours, we also evaluated nuclear texture within 
this group of paired tumours. DAPI staining was performed on TMA slides to 
visualise nuclei, and parameters representing nuclear texture were analysed using 
ImageJ as described before. From these images we observed similar morphological 
changes in the nuclei of several patients, with more heterogeneous structures 
presented compared with samples from the same patients before chemotherapy (see 
representative images from on patient in Figure 3.6-3). The observation is consistent 
with our findings above.   
 
Pre-treatment                                           Post-treatment 
   
Figure 3.6-3 Representative microscope images taken for nuclear texture analysis in one patient 
with ovarian cancer pre- and post-chemotherapy.  
 
We also quantified the morphological alterations in terms of nuclear texture, using 
our established method. Among these nuclear parameters mentioned above, 
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correlation and inverse difference moment (IDM) showed significant reductions in 
nuclei from patients after chemotherapy, suggesting increased heterogeneity and 
contrast of chromatin patterns, respectively (refer to Figure S2 in supplement for full 
data analysis).      
 
 
Figure 3.6-4 Comparison of nucelar texture parameters between paired samples from ovarian 
cancer patients pre- and post-chemotherapy. Tumour samples were spotted onto TMA slides, 
and nuclei were stained using DAPI. Fluorescent images were analysed using ImageJ, and 
nuclear texture was measured through several texture-related parameters among which 
significant changes are presented here. The Wilcoxon test was run for paried sample  
comparison and P values are indicated. 
     
Here I identified enhanced expression of HDAC and HP1 proteins in cancers after 
chemotherapy in patients, which also was accompanied by nuclear morphological 
alteration with increased heterogeneity of chromatin pattern. The result is consistent 
with our hypothesis and showed the association of HDAC with chromatin 
























4 Conclusions and discussion 
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The essential roles of epigenetic regulation for guarding genome integrity have been 
strongly emphasized in recent years. Along with this, the realisation that epigenetic 
regulation is also essential during the cellular DNA damage response also has risen, 
especially in cancer research. The relationship between chromatin status and DDR is 
far more complicated than we had originally expected. On one hand, the pre-existing 
condition of the chromatin structure can influence how cells response to extracellular 
damage. On the other hand, alteration of the chromatin environment on DNA 
damage is also an important component of the overall orchestration of the DDR 
pathways. Thus the network of epigenetic modifications of chromatin during DDR is 
only beginning to be understood, and little is known about the exact roles HDACs 
play during DDR events. In this study we identified similar alterations in chromatin 
pattern during DNA damage-based therapies in a variety of tumour settings from 
clinical patients, cell lines, and xenografts. We linked this phenomenon for the first 
time to HDAC expression, and suggest that this cellular change represents a response 
to damage that is mediated by HDACs and associated with DDR pathways in cancer 
cells. Study methods are illustrated in Figure 4-1. 
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Figure 4- 1 The investigation methodology used in this study to investigate the roles of HDACs 
in chromatin remodelling and DDR induced by DNA damage-based therapies.    
Firstly, quite similar nuclear morphological changes were observed across several 
tumours after cellualr damage including radiotherapy and chemotherapy, and those 
nuclear changes were measured in a robust way by measuring nuclear texture. In this 
way we were able to link the chromatin patterns occurring in cancer cells to the 
response to chemotherapy. The outcome of increased heterogeneity and decreased 
homogeneity was consistent with observations seen under the microscope, and 
provided a quantitative measure of this structural alteration in chromatin during 
DNA damage. Little is known and has been studied about nuclear morphological 
changes in response to DNA damage-induced treatment, but there are some data to 
support our observations. Fragmented nuclei and clumped chromatin in cancer cells 
have been observed after chemotherapy (Handelsman, Rondon et al. 1998; Marchetti 
2005), which also provided evidence to state that this nuclear change is a general 
phenomenon in cancers during either radiotherapy or chemotherapy. Due to the 









































hypothesised that this nuclear morphological change was a cellular response to 
external injuries. At the same time, results from antibody array studies performed in 
our laboratory showed that histone deacetylation status was able to distinguish cells 
in terms of exposure or response to platinum treatment. With the knowledge that 
histone acetylation is important for nuclear peripheralisation induced by DSBs 
(Peric-Concha and Long 2003), the nuclear morphological changes could 
mechanistically be connected to HDACs as a mediator of the response to DNA 
damage in cancer treatment, providing rationale for these studies. 
The nuclear change of elevated heterogeneity was assumed to be associated with 
increased transition from euchromatin and heterochromatin; therefore I tested 
heterochromatin formation during DNA damage-inducing treatment with platinum 
both in vivo and in vitro. As expected, expression of the heterochromatin marker, 
HP1 increased after cisplatin treatment in vitro, and this was accompanied by 
enhanced expression of HDAC2 at both mRNA and protein level. Studies in vivo and 
on clinical tumour samples also showed elevated expression of both HDAC and HP1 
after chemotherapy in ovarian cancer, especially in those sensitive to treatment. As 
an essential component of heterochromatin formation, HP1 has been already found to 
be accumulated or recruited to damaged sites in either UV-lesions or irradiation in a 
variety of studies (Leese, Hejaz et al. 2005; Bradley, Rathkopf et al. 2009; Di 
Bussolo and Minutolo 2011; Kim and Bae 2011), which indicates that chromatin 
reorganization occurs during DNA damage-based treatment. This study showed a 
similar result, with enhanced heterochromatin formation following  chemotherapy 
both in vivo and in vitro, and furthermore provided evidence that HDAC is a 
regulator involved in this response to chemotherapy.  HDAC was up-regulated after 
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24h of treatment with cisplatin in vitro, with similar results seen in vivo and in 
ovarian cancer xenografts. With its well-known function as a structural regulator to 
form condensed chromatin, HDAC potentially explained the observed changes in 
nuclear texture and was presumed to be a mediator during DDR. This alteration in 
chromatin pattern might also indicate that transcriptional silencing is occurring after 
chemotherapy, which might be a form of cellular self-protection upon injury. In fact, 
there is evidence demonstrating the participation of HDAC-containing complexes 
including Mi-2/NuRD and/or Sin3/HDAC chromatin-modifying complex (containing 
HDAC1 and HDAC2) in the reorganisation of nuclear structure for their repressive 
function during development (Stronach, Alfraidi et al. 2011). Other studies have also 
shown that Mi-2/NuRD and mSin3/HDAC co-repressor complexes are necessary for 
the process of pericentric heterochromatin assembly and chromosome segregation 
(Kartalou and Essigmann 2001; Kim, Kim et al. 2013).  
To explore the detailed roles of HDAC during chemotherapy in cells in our study, I 
next evaluated its effect on cell growth. HDACs are associated with malignancy and 
poor clinical outcomes in several cancers (Kothandapani, Dangeti et al. 2011), and 
this suggests a possible function in tumour growth, invasion, and even metastasis in 
cancer. Moreover, a range of studies have shown the potential effect of HDAC 
inhibition on cancer cell growth (Podhorecka, Halicka et al. 2009; Atsumi, Inase et al. 
2013; Lu, Xiong et al. 2013), which makes HDAC inhibitors exciting drug 
candidates for cancer treatment. A number of studies have also demonstrated 
effective combinatorial treatment with both HDAC inhibitors and chemotherapy in 
cancers. One HDAC inhibitor, Romidepsin (FK228), which is approved in phase I 
and II trials, enhances the cytotoxic effects of cisplatin by reducing cell growth and 
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causing more DNA damage-induced cell death when used in combination both in 
vitro and in vivo (Lu, Shi et al. 2008). I also demonstrated the inhibitory effect of the 
HDAC inhibitor TSA on ovarian cancer cells when treating the cells with TSA alone 
or TSA and cisplatin. Since HDAC2 in particular was associated with the early 
response to cisplatin in our cell culture studies, cell growth was further evaluated 
with HDAC2 knockdown using siRNA. The IC50 of cisplatin was significantly 
reduced by HDAC2 depletion in both PEO1 and PEO4 cells, which means specific 
knockdown of HDAC2 contributed to the effect of cisplatin treatment; however, this 
effect is additive and at this point there is a shortage of evidence to elucidate if there 
is synergistic mechanism for HDAC2 in the cellular response to cisplatin. Follow-on 
experiments indeed suggested the distinct roles for HDAC2 in regulating the cell 
cycle distribution and apoptosis induced by cisplatin in sensitive and resistant cell 
lines. Increased cellular apoptosis in both cell lines could be the reason for cell 
growth inhibition induced by HDAC2 knockdown during cisplatin treatment, and 
this induction of apoptosis might result from activation of different pathways. It 
seems that the repression of cell growth in sensitive PEO1 cells by cisplatin after 
HDAC2 silencing is caused by induction of apoptosis through accumulated S phase 
arrest, based on single treatment with cisplatin. In contrast, HDAC2 depletion 
seemed to resume the cell cycle in PEO4 cells treated with cisplatin, which means 
apoptosis is induced by cisplatin after HDAC2 knockdown by restoring cell cycle 
progression. The differences here between PEO1 and PEO4 cells indicated that 
HDAC2 might function via different pathways to participate in the cellular response 
to cisplatin treatment, and also in another way implies the distinct characteristics 
between the cell lines in terms of cisplatin sensitivity. The blockage of cell cycle 
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progression has been reported to occur as a result of checkpoint activation during 
DNA damage-based therapy, and one of the representative checkpoint proteins, Chk1, 
showed up-regulation in the process of intra-S phase accumulation by affecting 
chromatin formation and interfering with initiation and elongation of DNA 
replication (Liu, Parry et al. 2008). I therefore suppose that HDAC2 might interact 
with those checkpoint proteins to prevent DNA replication by forming a condensed 
structure as a type of self-protection, and also be involved in distinct pathways to 
trigger apoptosis induced by cisplatin between sensitive and resistant cells.  Several 
mechanisms have been suggested to explain HDAC inhibitor-induced apoptosis, 
such as altered gene transcription and modified DDR and DNA damage repair 
proteins (Lu, Zhu et al. 2006; Tanaka, Kurose et al. 2006; Zykova, Zhu et al. 2006).  
Early up-regulation (after 24h) of HDAC2 in sensitive cells suggests that HDAC2 is 
acting as a sensor of DNA damage, while the relative global down-regulation of all 
the HDACs measured was observed after 48h treatment in a time-dependent manner. 
This occurred along with up-regulation of DDR proteins, suggesting that DDR is 
active throughout the observed time course. I assumed that an initial accumulation of 
HDAC2 was required upon damage to trigger downstream DDR events (such as 
activation of ATM, ATR, and BRCA1) and chromatin remodelling, followed by 
histone hyperacetylation to form a less condensed structure to facilitate the 
recruitment of more DDR mediators to the damaged site. Therefore, more detailed 
involvement of HDAC was assessed by profiling the expression of proteins known to 
play key roles in the DDR (pBRCA1, ATM, ATR, γH2AX, and Rad51) during 
cisplatin treatment after HDAC2 knockdown. The accumulation of DSBs measured 
by γH2AX expression was demonstrated after 24 hours of cisplatin treatment in 
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PEO1 cells with HDAC2 depletion, and this cumulative effect from both siHDAC 
and cisplatin seemed to be gradually lost during incubation until 72h. However, a 
similar result was not present in PEO4 cells. Moreover, the γH2AX foci assay also 
confirmed distinct roles for HDAC2 in DSB formation between sensitive and 
resistant cells. High expression levels of γH2AX have previously been associated 
with cell viability and apoptosis in ovarian cancer (Lu, Zhu et al. 2006), which was 
attributed to the cell type tested and observation time after damage. Quite late H2AX 
activation has also been noted a number of days after treatment with an HDAC 
inhibitor, which implies increased expression of γH2AX occurs as a consequence to 
cancer cell death (Huang, Kurose et al. 2006). Suppression of DDR activation 
(pATM, pATR, pBRCA1, and RAD51) after HDAC2 knockdown strongly suggests 
involvement of HDAC2 in the cellular response to the DNA damage-based treatment. 
Distinct results between PEO1 and PEO4 cells in DSB accumulation and time of 
pathway activation or suppression is consistent with the differences mentioned above 
in cell cycle progression, and also might be due to the character of the two cell lines 
in terms of their cisplatin sensitivity. The two major pathways for DSB repair, NHEJ 
and HR, are suggested to have a compensatory effect with respect to each other 
(Jeggo, Geuting et al. 2011), and the balance between them might be disrupted by the 
distinct status of BRCA2 in PEO1 (BRCA2 deficiency) and PEO4 (secondary 
mutation to restore BRCA2 proficiency) cells, which might influence the dominant 
mechanism of repair in the two cell lines and cause differences in the observed 
functional activity of the measured DNA damage response proteins at different 
stages after cisplatin treatment. 
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A main challenge in this study was to reverse the observed nuclear changes by 
knocking down HDAC to show the causative effect of HDAC in mediating the 
morphological alterations. If the epigenetic modifications were indeed reversible, the 
chromatin structure should have been altered after HDAC2 depletion. This did occur, 
at least in part, with the textural parameters tending to indicate more homogeneity 
after HDAC2 knockdown. However, the result was more complicated than expected, 
and several possibilities were considered. Firstly, previous studies have shown that 
the immediate DDR occurs within minutes after damage (Trainor, Butterworth et al. 
2012), so it is likely that the ideal observation time point was missed based on the 
assumption that HDAC2 was an early mediator of the DNA damage response. 
Furthermore, the compensatory effect of HDAC1 from HDAC2 depletion also needs 
to be taken into account, which might have reduced or mitigated the effects of 
HDAC2 knockdown; additionally, HDAC2 knockdown might affect the balance 
between HDAC and other chromatin structural regulators, with a negative feedback 
effect causing complex alterations in chromatin patterns. Last, but not least, the 
toxicity from transfection cannot be completely excluded, which also is considered 
as an injury to the cells and therefore be assumed to cause chromatin reorganization 
if our hypothesis is correct. Further studies might be done through more 
comprehensive profiling, or using a different model such as stable HDAC2 
knockdown models. 
All these results suggest that chromatin remodelling caused by increased expression 
of HDACs might be an early cellular event (within 24h) in response to DNA damage 
treatment, and also indicated the possible involvement of HDACs in the DNA 
damage response in ovarian cancer. We postulate that in sensitive tumours, the early 
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alteration in the chromatin pattern induced by chemotherapy mediated by histone 
deacetylation serves as a form of cellular ‘self-defense’ to extra injury, which is also 
a necessary step to slow down transcription, initiate downstream events during 
chemotherapy-triggered DDR, and promote survival. This is followed by alteration 
to a less condensed chromatin conformation through histone hyperacetylation, such 
as via H3k56Ac and H4k16Ac, which is suggested to provide accessibility of 
downstream proteins into damaged sites to precede DDR (Kurose, Tanaka et al. 
2005; Kurose, Tanaka et al. 2006; Tanaka, Kurose et al. 2006).  However, resistant 
tumours behave differently in terms of their response to DNA damage to 
chemotherapy; this might be due to their initial chromatin environment, or due to 
other changes in the components of the DDR response pathways that HDACs also 
participate in (model illustrated in Figure 4-2).  
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Figure 4- 2 A proposed model of the role of HDACs based on the study. 
 
Interestingly, one important published study supports these assumptions, with 
HDAC1/2-associated immediate histone hypoacetylation occurring after laser 
microirradiation in an human osteosarcoma cell line to promote NHEJ, which was 
followed by hypoacetylation to enhance HR and guard genome integrity (Miller, 
Tjeertes et al. 2010). These data also provide evidence about the roles of HDACs in 
cellular DDR in a dynamic way, which makes studies in this field rather complicated. 
Several issues are raised based on our studies worthy of future investigation. 
Different HDAC family members showed the potential to mediate chemotherapy-
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induced DDR in this study. Apart from limitations caused by tissue heterogeneity 
and sample size which could be responsible for differing results, it also highlights the 
possibility that HDACs function in a tissue or cell type-dependent manner, and raises 
the importance of investigating their roles in more specific cancer types. or even 
subtypes, for drug development. Secondly, caution in interpretation of the cell 
culture studies described here, since different chromatin densities and radiation 
sensitivities have been observed between two- and three-dimensional cell cultures 
(Halicka, Huang et al. 2005). This might also be a reason for differing results in vitro 
and in vivo; in the future, 3D cultures may be a more accurate model to investigate. 
Moreover, cytotoxity from siRNA knockdown cannot be completely excluded, 
although we showed little effect on expression of other HDAC family members and 
included several controls throughout the experimental design. This may have limited 
our evaluation of reversal of nuclear texture after HDAC knockdown. Stable 
knockout of specific HDACs might be useful step to identify their roles in this 
system, and dual silencing of HDAC1 and HDAC2 should also be included due to 
their identified compensatory effect to each other (Jurkin, Zupkovitz et al. 2011). 
Fourthly, besides their epigenetic function in regulating chromatin structure, HDACs 
possess both nuclear and cytoplasmic functions, and a number of studies have linked 
their roles during DDR with deacetylation of non-histone proteins (Huang, Traganos 
et al. 2003; Robert, Vanoli et al. 2011). Therefore, further studies on HDAC cellular 
localization, and even co-localization with DDR proteins at damaged sites, are 
essential to solve these questions and showed clear evidence of the participation of 
HDACs at damaged sites to promote cellular DDR events. Furthermore, with the 
current opinion about re-modelling factors orchestrating the modification of 
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chromatin structure (Rogakou, Nieves-Neira et al. 2000), investigation is urgently 
required about how HDACs function during DDR along with other chromatin 
modifiers, such as DNA/histone methylation and poly-ADP-ribosylation. 
This study for the first time associates the cellular morphological changes seen in 
real human cancers with possible molecular mechanisms mediating this phenomenon, 
contributes to current knowledge about epigenetic regulation during chemotherapy-
induced DNA damage responses, and also suggests an additive effect of HDACs in 
terms of the cellular response to chemotherapy. By identifying more detailed roles of 
HDACs in cellular DNA damage responses in terms of chromatin remodelling, we 
hope to better understand the molecular processes behind these morphological 
alterations to identify novel mechanisms of response to chemotherapy in ovarian 
cancer, and other cancers and diseases. In this way HDACi can be better tailored as a 
therapeutic option and further developed to provide new targets, or combinatorial 
strategies, for the treatment of cancer and other diseases. 
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Table S3 Tukey HSD Post Hoc test following one-way ANOVA analysis for comparison between 
groups during knockdown of HDAC2 in PEO1 cells. 
 




negative control .840 
siHDAC2 10pmol .094 
siHDAC2 100pmol .001 
mock 
untransfected .942 
negative control .998 
siHDAC2 10pmol .276 





siHDAC2 10pmol .396 





negative control .396 





negative control .003 




negative control .231 
siHDAC2 10pmol .000 
siHDAC2 100pmol .000 
mock 
untransfected .201 
negative control 1.000 
siHDAC2 10pmol .000 





siHDAC2 10pmol .000 





negative control .000 





negative control .000 














negative control 1.000 
siHDAC2 10pmol .001 
siHDAC2 100pmol .001 
mock 
untransfected .713 
negative control .693 
siHDAC2 10pmol .000 





siHDAC2 10pmol .001 





negative control .001 





negative control .001 




negative control .811 
siHDAC2 10pmol .000 
siHDAC2 100pmol .000 
mock 
untransfected .030 
negative control .159 
siHDAC2 10pmol .000 





siHDAC2 10pmol .000 





negative control .000 





negative control .000 
siHDAC2 10pmol .970 
 
Table S4 Tukey HSD Post Hoc test following one-way ANOVA analysis for comparison between 




Cell line Treatment Treatment Sig. 
PEO1 foci counting NC NC+cis .000 
siRNA .004 
siRNA+cis .000 
NC+cis NC .000 
siRNA .053 
siRNA+cis .028 
siRNA NC .004 
NC+cis .053 
siRNA+cis .001 
siRNA+cis NC .000 
NC+cis .028 
siRNA .001 
PEO4 foci counting NC NC+cis .000 
siRNA .887 
siRNA+cis .032 
NC+cis NC .000 
siRNA .001 
siRNA+cis .019 
siRNA NC .887 
NC+cis .001 
siRNA+cis .088 




Table S5 Games-Howell pot HOC test was performed to compare between groups for cell cycle 
distribution with cisplatin treatment in PEO1 and PEO4 cells after HDAC2 knockdown. 
 
 PEO1 
  Mock NC siRNA Untransfected 
+Cis 
Mock+ Cis NC+Cis siRNA+Cis 
G1 
Untransfected .996 .240 .994 .000 .000 .000 .000 
Mock  .198 .917 .000 .000 .000 .000 
NC   .297 .001 .000 .000 .000 
siRNA    .000 .000 .000 .000 
Untransfected
+Cis 
    .994 .070 .000 
Mock+Cis      .779 .001 
NC+Cis       .000 
S 
Untransfected .220 1.0000 .001 .000 .001 .000 .000 
Mock  .763 .000 .000 .001 .000 .000 
NC   .034 .001 .000 .001 .000 
siRNA    .000 .003 .000 .000 
Untransfected
+Cis 
    .696 .273 .000 
Mock+Cis      .258 .004 
NC+Cis       .000 
G2 
Untransfected .131 .998 .000 .001 .001 .000 .000 
Mock  .758 .000 .001 .001 .000 .000 
NC   .006 .007 .001 .001 .001 
siRNA    .934 .317 .785 .137 
Untransfected
+Cis 
    .371 .630 .127 
Mock+Cis      .175 .043 











  Mock NC siRNA Untransfected 
+Cis 
Mock+ Cis NC+Cis siRNA+Cis 
G1 
Untransfected .849 .962 .169 .605 .010 .003 .010 
Mock  1.000 .160 .598 .002 .003 .013 
NC   .156 .599 .001 .003 .011 
siRNA    .743 .000 .000 .007 
Untransfected
+Cis 
    .950 .887 .997 
Mock+Cis      .496 .002 
NC+Cis       .001 
S 
Untransfected .391 .999 .812 .596 .000 .000 .002 
Mock  .455 .266 .570 .000 .001 .005 
NC   .647 .591 .000 .000 .003 
siRNA    .621 .000 .000 .001 
Untransfected
+Cis 
    .941 .946 .994 
Mock+Cis      1.000 .001 
NC+Cis       .001 
G2 
Untransfected .921 .660 .057 .610 .006 .047 .000 
Mock  .899 .173 .757 .005 .039 .003 
NC   .971 .992 .115 .104 .026 
siRNA    1.000 .022 .113 .003 
Untransfected
+Cis 
    .471 .438 .083 
Mock+Cis      1.000 .012 










Table S6 Tukey HSD pot HOC test was performed to compare between groups for apoptosis 
with cisplatin treatment in PEO1 and PEO4 cells after HDAC2 knockdown. 
 PEO1 
  Mock NC siRNA Untransfected 
+Cis 









Untransfected 1.000 .931 .029 .055 .055 .337 .047 
Mock  1.000 .017 .273 .264 .311 .014 
NC   .039 .076 .032 .360 .052 
siRNA    .028 .073 .113 .066 
Untransfected
+Cis 
    .608 .865 .047 
Mock+Cis      .981 .067 









Untransfected 1.000 1.000 .132 .494 .793 1.000 .218 
Mock  1.000 .144 .562 .882 1.000 .234 
NC   .128 .495 .805 1.000 .214 
siRNA    .131 .133 .059 .770 
Untransfected
+Cis 
    .894 .260 .126 
Mock+Cis      0.736 .226 
NC+Cis       .068 
 
 PEO4 
  Mock NC siRNA Untransfected 
+Cis 









Untransfected 1.000 .928 .053 .854 .786 .619 .001 
Mock  0.947 .016 .846 .781 .600 .020 
NC   .019 .972 .949 .774 .017 
siRNA    .073 .048 .053 .119 
Untransfected
+Cis 
    1.000 .999 .083 
Mock+Cis      .998 .067 









Untransfected 1.000 .997 .442 .919 .999 1.000 .404 
Mock  1.000 .463 .953 1.000 1.000 .426 
NC   .488 .914 1.000 1.000 .456 
siRNA    .557 .480 .471 1.000 
Untransfected
+Cis 
    .920 .920 .516 
Mock+Cis      1.000 .447 
NC+Cis       .436 
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Table S7 Proteins included and grouped in accociated pathways in V250 proteomic study 
Proteins detected Associated pathways 
Estrogen Receptor-alpha (Phospho-Ser167) ER 
Rac1/cdc42(Phospho-Ser71)  MAPK 
Raf1(Phospho-Ser259)  MAPK 
MEK1(Phospho-Ser217)  MAPK 
MEK1(Phospho-Ser221)  MAPK 
MEK1(Phospho-Thr291)  MAPK 
MEK-2(Phospho-Thr394)  MAPK 
p44/42 MAP Kinase(Phospho-Thr202)  MAPK 
p44/42 MAP Kinase(Phospho-Tyr204)  MAPK 
Elk-1(Phospho-Ser383)  MAPK 
NF kappa B-p100/p52(Phospho-Ser869)  NF kappa B 
NF kappa B-p105/p50(Phospho-Ser893)  NF kappa B 
NF kappa B-p105/p50(Phospho-Ser907)  NF kappa B 
NF kappa B-p105/p50(Phospho-Ser932)  NF kappa B 
NF kappa B-p65(Phospho-Ser529)  NF kappa B 
NF kappa B-p65(Phospho-Thr254)  NF kappa B 
I-kappa-B-alpha(Phospho-Ser32/Phospho-Ser36 NF kappa B 
I-kappaB-alpha(Phospho-Tyr42)  NF kappa B 
I-kappa-B-beta(Phospho-Ser23) NF kappa B 
I-kappa-B-epsilon(Phospho-Ser22) NF kappa B 
IKK alpha(Phospho-Thr23)  NF kappa B 
Rel(Phospho-Ser503)  NF kappa B 
JAK1(Phospho-Tyr1022)  JAK/STAT 
JAK2(Phospho-Tyr1007)  JAK/STAT 
JAK2(Phospho-Tyr221)  JAK/STAT 
STAT1(Phospho-Ser727)  JAK/STAT 
STAT1(Phospho-Tyr701)  JAK/STAT 
STAT3(Phospho-Ser727)  JAK/STAT 
STAT3(Phospho-Tyr705)  JAK/STAT 
STAT4(Phospho-Tyr693)  JAK/STAT 
STAT5A (Phospho-Ser780)  JAK/STAT 
STAT5A (Phospho-Tyr694)  JAK/STAT 
STAT6(Phospho-Thr645)  JAK/STAT 
STAT6(Phospho-Tyr641)  JAK/STAT 
TYK2(Phospho-Tyr1054)  JAK/STAT 
Beta-Catenin Beta-Catenin 
Beta-Catenin(Phospho-Ser37)  Beta-Catenin 
Beta-Catenin(Phospho-Thr41/Phospho-Ser45 Beta-Catenin 
BAD(Phospho-Ser112)  Mitochondrial Apoptosis 
BAD(Phospho-Ser136)  Mitochondrial Apoptosis 
BAD(Phospho-Ser155)  Mitochondrial Apoptosis 
BCL-2(Phospho-Ser70)  Mitochondrial Apoptosis 
BCL-2(Phospho-Thr56)  Mitochondrial Apoptosis 
BCL-XL(Phospho-Ser62)  Mitochondrial Apoptosis 
Rb(Phospho-Ser780)  Early cell cycle 
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Proteins detected  Associated pathways 
CDK2(Phospho-Thr160)  Early cell cycle 
p21Cip1(Phospho-Thr145)  Early cell cycle 
p27Kip1(Phospho-Ser10)  Early cell cycle 
p27Kip1(Phospho-Thr187)  Early cell cycle 
FKHR(Phospho-Ser256)  Early cell cycle 
p53(Phospho-Ser315)  Late cell cycle/DNA damage 
p53(Phospho-Ser6)  Late cell cycle/DNA damage 
Chk1(Phospho-Ser280)  Late cell cycle/DNA damage 
Chk1(Phospho-Ser317)  Late cell cycle/DNA damage 
Chk1(Phospho-Ser345)  Late cell cycle/DNA damage 
Chk2(Phospho-Ser516)  Late cell cycle/DNA damage 
Chk2(Phospho-Thr68)  Late cell cycle/DNA damage 
CDC2(Phospho-Tyr15)  Late cell cycle/DNA damage 
cdc25A (Phospho-Ser75)  Late cell cycle/DNA damage 
cdc25C(Phospho-Ser216)  Late cell cycle/DNA damage 
BRCA1(Phospho-Ser1423)  Late cell cycle/DNA damage 
BRCA1(Phospho-Ser1524)  Late cell cycle/DNA damage 
Histone H2A.X(Phospho-Ser139)  Late cell cycle/DNA damage 
Akt(Phospho-Ser473)  AKT/mTOR 
Akt(Phospho-Thr308)  AKT/mTOR 




mTOR(Phospho-Ser2448)  AKT/mTOR 
GSK3-alpha(Phospho-Ser21)  AKT/mTOR 
GSK3-beta(Phospho-Ser9)  AKT/mTOR 
p70 S6 Kinase (Phospho-Ser424)  AKT/mTOR 
4E-BP1(Phospho-Thr36)  AKT/mTOR 
PDK1(Phospho-Ser241)  AKT/mTOR 
AMPK1(Phospho-Thr174) AKT/mTOR/AMPK 
P38 MAPK(Phospho-Thr180)  P38 MAPK 
P38 MAPK(Phospho-Tyr182)  P38 MAPK 
MKK3(Phospho-Ser189)  P38 MAPK 
SAPK/JNK(Phospho-Thr183)  P38 MAPK 
Myc(Phospho-Ser62) Transcriptional regulation 
Myc(Phospho-Thr358)  Transcriptional regulation 
Myc(Phospho-Thr58)  Transcriptional regulation 
JunB(Phospho-Ser259)  Transcriptional regulation 
JunB(Phospho-Ser79)  Transcriptional regulation 
JunD(Phospho-Ser255)  Transcriptional regulation 
c-Jun (Phospho-Thr239)  Transcriptional regulation 
c-Jun(Phospho-Ser243)  Transcriptional regulation 
c-Jun(Phospho-Ser73)  Transcriptional regulation 
CREB(Phospho-Ser133)  Transcriptional regulation 
Trk B(Phospho-Tyr515) Tyrosine kinase/adapters 
c-Kit(Phospho-Tyr721)  Tyrosine kinase/adapters 
EGFR(Phospho-Tyr1110)  Tyrosine kinase/adapters 
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Proteins detected Associated pathways 
FGF Receptor 1(Phospho-Tyr154)  Tyrosine kinase/adapters 
IGF-1R (Phospho-Tyr1161)  Tyrosine kinase/adapters 
Met(Phospho-Tyr1349)  Tyrosine kinase/adapters 
PDGF Receptor beta(Phospho-Tyr751)  Tyrosine kinase/adapters 
VEGFR2(Phospho-Tyr951)  Tyrosine kinase/adapters 
HER2(Phospho-Tyr877)  Tyrosine kinase/adapters 
CrkII(Phospho-Tyr221) Tyrosine kinase/adapters 
FAK(Phospho-Tyr861)  Tyrosine kinase/adapters 
FAK(Phospho-Tyr925)  Tyrosine kinase/adapters 
Pyk2(Phospho-Tyr402)  Tyrosine kinase/adapters 
Src(Phospho-Tyr418)  Tyrosine kinase/adapters 
Src(Phospho-Tyr529)  Tyrosine kinase/adapters 
Shc(Phospho-Tyr349) Tyrosine kinase/adapters 
SHP-2(Phospho-Tyr580) Tyrosine kinase/adapters 
HSF1(Phospho-Ser303)  Heat-shock 
HSP27(Phospho-Ser15)  Heat-shock 
HSP27(Phospho-Ser78)  Heat-shock 
HSP90B(Phospho-Ser254) Heat-shock 
ICAM-1(Phospho-Tyr512)  Adhesion/cell contact 
Integrin beta-3(Phospho-Tyr773)  Adhesion/cell contact 
Integrin beta-3(Phospho-Tyr785)  Adhesion/cell contact 
Smad3(Phospho-Ser425) SMAD 
eEF2K(Phospho-Ser366) Calcium 
CaMKII (Phospho-Thr286)  Calcium 
Caveolin-1(Phospho-Tyr14)  Cholesterol/lipid 
eIF2 alpha(Phospho-Ser51)  Transcriptional regulation 
elF4E(Phospho-Ser209)  Transcriptional regulation 
HDAC8(Phospho-Ser39)  Deacetylation 
Keratin 18(Phospho-Ser33) Structural 
Tau(Phospho-Ser404)  Structural 
14-3-3 Zeta(Phospho-Ser58) Misc 
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5.2 Supplement Materials 
5.2.1 Cell culture reagents 
Product                                                           Manufactures or Supplier/Catalogue No. 
Penicillin / Streptomycin                                           Invitrogen/15140-122 
Trypsin-EDTA                                                           Invitrogen/25300 
Dulbecco’s minimal essential media (DMEM)         Gibco/21875-091 
Fetal calf serum                                                        Harlen Sera-Lab LTD/S-0001 AE 
PBS tablets                                                                 OXOID/BR0014G 
5.2.2 Reagents for treatment 
Product                                                                      Manufactures/Supplier 
Trichostatin A (TSA)                                                 Calbiochem  
Cisplatin                                                                     TEVA 
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5.2.3 Reagents for protein detection in cell lines 
 
Product                                                             Manufactures or Supplier/catalogue   
Mini complete protease  
inhibitor cocktail tablets  
Aprotinin 
Phosphatase inhibitor  
cocktail 1  
Phosphatase inhibitor  
cocktail 2 
CNMCS Compartmental  
Protein Extraction Kit  
30% acrylamide/Bis  










Biochain Institute, Inc., CA, 
USA/K3013010  




BDH Laboratory supplies /102246L  





Odyssey Blocking Buffer  
Roche Applied Science/11836153001 
LI-COR Biosciences/927-40000  
5.2.4 Reagents for protein detection in tumours 
 
Product                                                             Manufactures/Supplier 
DAKO Protein Block  
Serum Free 
DAKO Antibody Diluent  
Dako Envision+System-  
HRP labelled polymer  
Anti-rabbit 
Dako Envision+System-  
HRP labelled polymer  
Anti-mouse 
DAB chromogen  
Mouse anti-cytokeratin  
(Pan) antibody 
















AquantiplexTM assay kit  
Prolong Gold anti-fade  
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